WO2006095020A1 - Heterocyclic-substituted alkanamides useful as renin inhibitors - Google Patents

Heterocyclic-substituted alkanamides useful as renin inhibitors Download PDF

Info

Publication number
WO2006095020A1
WO2006095020A1 PCT/EP2006/060625 EP2006060625W WO2006095020A1 WO 2006095020 A1 WO2006095020 A1 WO 2006095020A1 EP 2006060625 W EP2006060625 W EP 2006060625W WO 2006095020 A1 WO2006095020 A1 WO 2006095020A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkoxy
alkyl
methyl
methoxypropoxy
amino
Prior art date
Application number
PCT/EP2006/060625
Other languages
French (fr)
Inventor
Peter Herold
Robert Mah
Vincenzo Tschinke
Stefan Stutz
Dirk Behnke
Aleksandar Stojanovic
Stjepan Jelakovic
Christiane Marti
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Priority to EP06725011A priority Critical patent/EP1856032A1/en
Priority to JP2008500210A priority patent/JP2008532983A/en
Priority to BRPI0609158-0A priority patent/BRPI0609158A2/en
Priority to US11/885,967 priority patent/US20080176947A1/en
Priority to CA002600674A priority patent/CA2600674A1/en
Publication of WO2006095020A1 publication Critical patent/WO2006095020A1/en
Priority to IL185769A priority patent/IL185769A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/04—Seven-membered rings not condensed with other rings
    • C07D321/08—1,4-Dioxepines; Hydrogenated 1,4-dioxepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Definitions

  • the present invention relates to novel alkanamides, process for their preparation and the use of the compounds as medicines, especially as renin inhibitors.
  • Alkanamides for use as medicines are disclosed for example in EP 0678503.
  • renin inhibition In relation especially to the renin inhibition, however, there is still a need for active ingredients of high potency.
  • the priority in this is to improve the pharmacokinetic properties. These properties, which aim at better bioavailability, are for example absorption, metabolic stability, solubility or lipophilicity.
  • the invention therefore provides compounds of the general formula
  • R 1 is a) saturated heterocyclyl which is optionally substituted one or more times by Ci -8 - alkanoyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 alkoxy, Ci -6 alkoxy-Ci -6 alkoxy, Ci -6 alkoxy-Ci -6 alkyl, Ci -6 alkoxycarbonylamino, Ci -6 alkyl, C 0-6 alkylcarbonylamino, Ci -6 alkylcarbonyloxy, Ci -6 alkylenedioxy, optionally N-mono or N,N-di-Ci -6 -alkylated amino, aryl, optionally N-mono or N,N-di-Ci -6 -alkylated carbamoyl, optionally esterified carboxy, cyano, C 3-8 cycloalkoxy, Cs-scycloalkyl-Co-ealkyl, halogen, halo-Ci -6 alkoxy
  • R 2 is, independently of one another, 1-4 radicals selected from:
  • saturated heterocyclyl refers to 3-16-membered, mono- or bicyclic saturated heterocyclic radicals having 1 to 4 nitrogen and/or 1 or 2 sulphur or oxygen atoms.
  • Preferred radicals have 3-8 members, particularly preferably 5 or 6 members, and are monocyclic and are optionally fused to a 3-8-membered ring which may be carbocyclic or heterocyclic.
  • a further preferred group of heterocyclic radicals are bicyclic heterocycles which have a spiro- cyclic or bridged ring.
  • Preferred heterocyclic radicals have in each ring 1 nitrogen, oxygen or sulphur atom, 1-2 nitrogen atoms and 1-2 oxygen atoms or 1-2 nitrogen atoms and 1-2 sulphur atoms, with at least one, preferably 1-7, carbon atom(s) being present in each ring.
  • heterocyclyl radicals are azepanyl, azetidinyl, aziridinyl, dioxanyl, [1,4]dioxepanyl, dioxolanyl, dithianyl, dithiolanyl, morpholinyl, oxathianyl, oxepanyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothio- phenyl, tetrahydrothiopyranyl, thiepanyl or thiomorpholinyl.
  • bicyclic heterocyclyl radicals are 2,5-dioxabicyclo[4.1.0]heptanyl, 2-oxabicyclo[2.2.1]heptanyl, 2-oxa- bicyclo[4.1.OJheptanyl, 3-oxabicyclo[4.1.OJheptanyl, 7-oxabicyclo[2.2.1]heptanyl, 2-oxabicyclo[3.1.0]hexanyl, 3-oxabicyclo[3.1.0]hexanyl, 1-oxaspiro[2.5]octanyl, 6-oxaspiro[2.5]octanyl or 3-oxabicyclo[3.3.1]nonanyl.
  • Heterocyclyl may be unsubstituted or substituted one or more times, e.g. once or twice, by Ci -8 alkanoyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 alkoxy, Ci -6 alkoxy-Ci -6 alkoxy, Ci -6 alkoxy-Ci -6 alkyl, Ci -6 alkoxycarbonylamino, Ci -6 alkyl, C 0-6 alkylcarbonylamino, Ci -6 alkylcarbonyloxy, - A -
  • Ci -6 alkylenedioxy optionally N-mono or N,N-di-Ci -6 -alkylated amino, aryl, optionally N-mono or N,N-di-Ci -6 -alkylated carbamoyl, optionally esterified carboxy, cyano, C 3-8 cycloalkoxy, Cs-scycloalkyl-Co-ealkyl, halogen, halo-Ci -6 alkoxy, halo-Ci -6 alkyl, heteroaryl, heterocyclyl, hydroxy, nitro, oxide or oxo.
  • Ci -8 Alkanoyl is, for example, formyl, ethanoyl, propanoyl or butanoyl.
  • Ci -6 Alkyl may be straight-chain or branched and/or bridged and is for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl or a pentyl or hexyl group.
  • Ci -6 Alkylamino is, for example, methylamino, ethylamino, propylamino or butylamino.
  • Di-Ci -6 alkylamino is, for example, dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-propylamino or N-butyl-N-methylamino.
  • C 2-6 Alkenyl may be straight-chain or branched and is, for example, allyl or vinyl
  • C 2-6 Alkynyl may be straight-chain or branched and is, for example, ethynyl.
  • Ci -6 Alkoxy is, for example, methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, secondary butyloxy, tertiary butyloxy, pentyloxy or hexyloxy.
  • Ci -6 Alkoxycarbonylamino is preferably C 2 -C 5 alkoxycarbonylamino such as ethoxycarbonyl- amino, propyloxycarbonylamino, isopropyloxycarbonylamino, butyloxycarbonylamino, isobutyloxycarbonylamino, secondary butyloxycarbonylamino or tertiary butyloxycarbonylamino.
  • Ci -6 Alkylcarbonyloxy is, for example, acetyloxy, propionyloxy, propylcarbonyloxy, isopropyl- carbonyloxy, butylcarbonyloxy, isobutylcarbonyloxy, secondary butylcarbonyloxy, tertiary butylcarbonyloxy, pentylcarbonyloxy or hexylcarbonyloxy.
  • Co- ⁇ Alkylcarbonylamino is, for example, formylamino, acetylamino, propionylamino, propyl- carbonylamino, isopropylcarbonylamino, butylcarbonylamino, isobutylcarbonylamino, secondary butylcarbonylamino, tertiary butylcarbonylamino, pentylcarbonylamino or hexylcarbonylamino.
  • Halogen is, for example, fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.
  • Halo-Ci -6 alkoxy is, for example, alkoxy substituted one or more times by fluorine, chlorine, bromine or iodine, including mixed, e.g. fluorine and chlorine, substitutions, with preference for perfluorinated radicals such as trifluoromethoxy.
  • Halo-Ci_ 6 alkyl is, for example, alkyl substituted one or more times by fluorine, chlorine, bromine or iodine, including mixed, e.g. fluorine and chlorine, substitutions, with preference for perfluorinated radicals such as trifluoromethyl.
  • Ci -6 Alkylenedioxy is, for example, methylenedioxy, ethylenedioxy, 1,3-propylenedioxy or 1 ,2-propylenedioxy.
  • N-mono or N,N-di-Ci -8 -alkylated carbamoyl is, for example, carbamoyl, methyl- carbamoyl, ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl or propyl- carbamoyl.
  • esterified carboxy is, for example, carboxy esterified with Co -6 alkyl, such as carboxy or Ci -6 alkoxycarbonyl.
  • Cycloal koxy is preferably 3-, 5- or 6-membered cycloalkoxy such as cyclopropyloxy, cyclopentyloxy and cyclohexyloxy.
  • Cycloal kyl-C 0-6 alkyl is preferably 3-, 5- or 6-membered cycloalkyl such as cyclopropyl, cyclopropylmethyl, cyclopentyl and cyclohexyl.
  • Cyano-Ci -4 alkoxy is, for example, cyanomethoxy, 2-cyanoethoxy, 2- or 3-cyanopropyloxy or 4-cya no butyl oxy, especially cyanomethoxy.
  • Cyano-Ci -4 alkyl is, for example, cyanomethyl, 2-cyanoethyl, 2- or 3-cyanopropyl, 2-cyano- 2-methylpropyl or 4-cyanobutyl, especially cyanomethyl.
  • N,N-Di-Ci -4 alkylamino is, for example, dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-propylamino or N-butyl-N-methylamino.
  • N,N-Di-Ci -4 alkylamino-Ci -4 alkoxy is 2-dimethylaminoethoxy, 3-dimethylaminopropyloxy, 4-dimethylaminobutyloxy, 2-diethylaminoethoxy, 2-(N-methyl-N-ethylamino)ethoxy or 2-(N-butyl-N-methylamino)ethoxy.
  • N,N-Di-Ci -4 alkylamino-Ci -4 alkyl is, for example, 2-dimethylaminoethyl, 3-dimethylamino- propyl, 4-dimethylaminobutyl, 2-diethylaminoethyl, 2-(N-methyl-N-ethylamino)ethyl or 2-(N-butyl-N-methylamino)ethyl.
  • N,N-Di-Ci -4 alkylcarbamoyl-Ci -4 alkoxy is, for example, methyl- or dimethylcarbamoyl- Ci -4 alkoxy such as N-methyl-, N-butyl- or N,N-dimethylcarbamoylmethoxy, 2-(N- methylcarbamoyl)ethoxy, 2-(N-butylcarbamoyl)ethoxy, 2-(N,N-dimethylcarbamoyl)ethoxy, 3-(N-methylcarbamoyl)propyloxy, 3-(N-butylcarbamoyl)propyloxy, 3-(N,N-dimethyl- carbamoyl)propyloxy or 4-(N-methylcarbamoyl)butyloxy, 4-(N-butylcarbamoyl)butyloxy or 4-(N,N-dimethylcarbamoyl)butyloxy, especially N
  • N.N-Di-Ci ⁇ alkylcarbamoyl-Ci ⁇ alkyl is, for example, 2-dimethylcarbamoylethyl, 3-dimethyl- carbamoylpropyl, 2-dimethylcarbamoylpropyl, 2-(dimethylcarbamoyl)-2-methylpropyl or 2-(dimethylcarbamoyl)butyl.
  • Optionally partially hydrogenated pyridyl- or N-oxidopyridyl-Ci -4 alkoxy is, for example, pyridyl- or N-oxidopyridylmethoxy, 2-pyridylethoxy, 2- or 3-pyridylpropyloxy or 4-pyridylbutyloxy, especially 3- or 4-pyridylmethoxy.
  • Optionally partially hydrogenated pyridyl- or N-oxidopyridyl-Ci -4 alkyl is, for example, pyridyl- or N-oxidopyridylmethyl, 2-pyridylethyl, 2- or 3-pyridylpropyl or 4-pyridyl butyl, especially 3- or 4-pyridyl methyl.
  • Morpholino-Ci -4 alkoxy may be N-oxidized and is, for example, 1-morpholinoethoxy, 3-morpholinopropyloxy or 1-(morpholino-2-methyl)propyloxy.
  • Morpholino-Ci -4 alkyl may be N-oxidized and is, for example, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl or 1- or 2-(4-morpholino)butyl.
  • Piperazino-Ci -4 alkyl is, for example, piperazinomethyl, 2-piperazinoethyl or 3-piperazinopropyl.
  • Piperidino-Ci -4 alkoxy is, for example, piperidinomethoxy, 2-piperidinoethoxy or 3-piperidinopropyloxy.
  • Piperidino-Ci -4 alkyl is, for example, piperidinomethyl, 2-piperidinoethyl or 3-piperidinopropyl.
  • Pyrrolidino-C 2-4 alkoxy is, for example, 2-pyrrolidinoethoxy or 3-pyrrolidinopropyloxy.
  • Pyrrolidino-Ci -4 alkyl is, for example, pyrrolidinomethyl, 2-pyrrolidinoethyl or 3- pyrrolidinopropyl.
  • S-Oxothiomorpholino-Ci -4 alkyl is, for example, S-oxothiomorpholinomethyl or 2-(S- oxothiomorpholino)ethyl.
  • Thiazolyl-Ci -4 alkoxy is, for example, thiazolylmethoxy, 2-thiazolylethoxy or 3-thiazolylpropyloxy.
  • Thiomorpholino-Ci -4 alkyl or S,S-dioxothiomorpholino-Ci -4 alkyl is, for example, thiomorpholino-Ci -4 alkyl such as -methyl or -ethyl, or S,S-dioxothiomorpholino-Ci -4 alkyl such as -methyl or -ethyl.
  • the compounds of the invention may be in the form of mixtures of isomers, specifically as racemates, or in the form of pure isomers, specifically of optical antipodes. The invention includes all these forms. Mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates can be fractionated by conventional methods, e.g. by column chromatography, thin-layer chromatography, HPLC and the like.
  • Salts of compounds with salt-forming groups are in particular acid addition salts, salts with bases or, if a plurality of salt-forming groups is present, optionally also mixed salts or inner salts.
  • Salts are primarily the pharmaceutically acceptable or non-toxic salts of compounds of the formula (I). Such salts are formed for example by compounds of the formula (I) having an acidic group, e.g. a carboxy or sulpho group, and are for example their salts with suitable bases, such as non-toxic metal salts derived from metals of group Ia, Ib, Na and Nb of the Periodic Table of the Elements, e.g.
  • alkali metal in particular lithium, sodium or potassium, salts, alkaline earth metal salts, for example magnesium or calcium salts, furthermore zinc salts or ammonium salts, also salts formed with organic amines such as optionally hydroxy- substituted mono-, di- or trialkylamines, especially mono-, di- or tri-lower-alkylamines, or with quaternary ammonium bases, e.g.
  • methyl-, ethyl-, diethyl- or triethylamine mono-, bis- or tris(2-hydroxy-lower-alkyl)amines such as ethanol-, diethanol- or triethanolamine, tris(hydroxymethyl)methylamine or 2-hydroxy-tertiary-butylamine, N.N-di-lower-alkyl- N-(hydroxy-lower-alkyl)amine, such as N,N-dimethyl-N-(2-hydroxyethyl)amine, or N-methyl- D-glucamine, or quaternary ammonium hydroxides such as tetrabutylammonium hydroxide.
  • an amino group can form acid addition salts, e.g. with suitable inorganic acids, e.g. hydrohalic acid such as hydrochloric acid, hydrobromic acid, sulphuric acid with replacement of one or both protons, phosphoric acid with replacement of one or more protons, e.g. orthophosphoric acid or metaphosphoric acid, or pyrophosphoric acid with replacement of one or more protons, or with organic car boxy lie, sulphonic or phosphonic acids or N-substituted sulphamic acids, e.g.
  • suitable inorganic acids e.g. hydrohalic acid such as hydrochloric acid, hydrobromic acid, sulphuric acid with replacement of one or both protons, phosphoric acid with replacement of one or more protons, e.g. orthophosphoric acid or metaphosphoric acid, or pyrophosphoric acid with replacement of one or more protons, or with organic car boxy lie, sulphonic or phosphonic acids or N-substituted
  • the compounds of the formula (I) also include compounds in which one or more atoms are replaced by their stable, non-radioactive isotopes; for example a hydrogen atom by deuterium.
  • Prodrug derivatives of the compounds described herein are derivatives thereof which on in vivo use liberate the original compound by a chemical or physiological process.
  • a prodrug may for example be converted into the original compound when a physiological pH is reached or by enzymatic conversion.
  • Possible examples of prodrug derivatives are esters of freely available carboxylic acids, S- and O-acyl derivatives of thiols, alcohols or phenols, the acyl group being defined as above.
  • Preferred derivatives are pharmaceutically acceptable ester derivatives which are converted by solvolysis in physiological medium into the original carboxylic acid, such as, for example, lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or disubstituted lower alkyl esters such as lower ⁇ -(amino, mono- or dialkylamino, carboxy, lower alkoxycarbonyl) - alkyl esters or such as lower ⁇ -(alkanoyloxy, alkoxycarbonyl or dialkylaminocarbonyl) - alkyl esters; conventionally, pivaloyloxymethyl esters and similar esters are used as such.
  • lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or disubstituted lower alkyl esters such as lower ⁇ -(amino, mono- or dialkylamino, carboxy, lower al
  • a particular compound in this invention also includes its prodrug derivative and salt form, where this is possible and appropriate.
  • R 1 has the meaning indicated for the compound of the formula (I) and
  • R' and R independently of one another, have the meanings indicated for R 2 for the compound of the formula (I).
  • R 2 is preferably, independently of one another, 1-4 radicals selected from: Ci- 8 alkanoylamino-Ci -4 alkoxy, N-Ci -4 alkanoylamino-Ci -4 alkyl, Ci -8 alkoxy, Ci -4 alkoxy-Ci -4 alkoxy, Ci -4 alkoxy-Ci -4 alkoxy-Ci -4 alkyl, Ci -4 alkoxy-Ci -4 alkyl, Ci-salkoxycarbonylamino-d ⁇ alkoxy, Ci-salkoxycarbonylamino-Ci ⁇ alkyl, Ci -8 alkyl, halogen, trifluoromethoxy and trifluoromethyl.
  • R 2 is particularly preferably, independently of one another, 1-4 radicals selected from: Ci -8 alkoxy, Ci -4 alkoxy-Ci -4 alkoxy, Ci -4 alkoxy-Ci -4 alkoxy-Ci -4 alkyl, Ci -4 alkoxy-Ci -4 alkyl, Ci -8 alkyl, halogen, trifluoromethoxy and trifluoromethyl.
  • R 1 is preferably optionally substituted C 2-6 alkynyl, optionally substituted saturated hetero- cyclyl bonded via a C atom or optionally substituted saturated bicyclic heterocyclyl-C 0-4 alkyl.
  • R 1 is particularly preferably optionally substituted C 2 - 6 alkynyl, optionally substituted saturated bicyclic heterocyclyl-C 0-4 alkyl, optionally substituted pyrrolidinyl, Ci -6 -alkylated or C 3-8 .
  • cycloalkyl-Co- 6 -alkylated piperidine optionally substituted tetrahydrofuranyl, optionally substituted tetrahydrofuranylmethyl, optionally substituted tetrahydropyranyl or optionally substituted tetrahydropyranyl methyl.
  • R 1 is particularly preferably also optionally substituted tetrahydrofuranylmethyl, optionally substituted tetrahydropyranyl methyl, optionally substituted saturated heterocyclyl which is bonded via a C atom or optionally substituted saturated bicyclic heterocyclyl-C 0-4 alkyl, where the heterocyclyl radical in each case comprises an oxygen atom as heteroatom. Also particularly preferred are compounds of the general formula (I') where
  • R' is N-Ci -4 alkanoylamino-Ci -4 alkyl, Ci -4 alkoxy-Ci -4 alkoxy-
  • Ci -4 alkyl Ci -4 alkoxy-Ci -4 alkoxy, Ci -4 alkoxy-Ci -4 alkyl, Ci-salkoxycarbonylamino-d ⁇ alkoxy or
  • R" is Ci -8 alkanoyl, Ci -8 alkoxy, Ci -8 alkyl, difluoroethyl, halogen, trifluoromethoxy or trifluoromethyl.
  • R' is Ci -4 alkoxy-Ci -4 alkoxy
  • R" is fluorine
  • R 1 is optionally substituted tetrahydrofuranylmethyl, optionally substituted tetrahydropyranyl- methyl, optionally substituted saturated heterocyclyl which is bonded via a C atom or optionally substituted saturated bicyclic heterocyclyl-Co ⁇ alkyl, where the heterocyclyl radical preferably in each case comprises an oxygen atom as heteroatom.
  • each case is those compounds of the formula I, in which at least one, for example one, two, three or, preferably, all four asymmetric C atoms of the main chain have the stereochemistry shown in formula IA ("S" in each case), where the substituents each have the meanings indicated above, and their pharmaceutically acceptable salts.
  • the compounds of the formula (I) can also be prepared in optically pure form. Separation into antipodes can take place by methods known per se, either preferably at an early stage in the synthesis by salt formation with an optically active acid such as, for example, (+)- or (-)-mandelic acid and separation of the diastereomeric salts by fractional crystallization or preferably at a rather late stage by derivatizing with a chiral auxiliary component such as, for example, (+)- or (-)-camphanoyl chloride, and separation of the diastereomeric products by chromatography and/or crystallization and subsequent cleavage of the linkage to the chiral auxiliary.
  • the pure diastereomeric salts and derivatives can be analysed to determine the absolute configuration of the contained piperidine by conventional spectroscopic methods, with X-ray spectroscopy on single crystals representing a particularly suitable method.
  • the compounds of the formula (I), and of the formula (IA), and their pharmaceutically acceptable salts have an inhibitory effect on the natural enzyme renin.
  • the latter passes from the kidneys into the blood and there brings about the cleavage of angiotensinogen to form the decapeptide angiotensin I which is then cleaved in the lung, the kidneys and other organs to the octapeptide angiotensin II.
  • Angiotensin Il raises the blood pressure both directly by arterial constriction, and indirectly by releasing the hormone aldosterone, which retains sodium ions, from the adrenals, which is associated with an increase in the extracellular fluid volume.
  • renin inhibitors The effect of renin inhibitors is detected inter alia experimentally by means of in vitro tests where the reduction in the formation of angiotensin I is measured in various systems (human plasma, purified human renin together with synthetic or natural renin substrate).
  • the IC 50 is defined as the concentration of the particular inhibitor which reduces the formation of angiotensin I by 50%.
  • the compounds of the present invention show inhibitory effects in the in vitro systems at minimal concentrations of about 10 ⁇ 6 to about 10 ⁇ 10 mol/l.
  • Renin inhibitors bring about a fall in blood pressure in salt-depleted animals.
  • Human renin differs from renin of other species. Inhibitors of human renin are tested using primates (marmosets, Callithrix jacchus) because human renin and primate renin are substantially homologous in the enzymatically active region. The following in vivo test is employed inter alia: the test compounds are tested on normotensive marmosets of both sexes with a body weight of about 350 g, which are conscious, unrestrained and in their normal cages. Blood pressure and heart rate are measured with a catheter in the descending aorta and are recorded radiometrically.
  • Endogenous release of renin is stimulated by combining a low-salt diet for 1 week with a single intramuscular injection of furosemide (5-(aminosulphonyl)- 4-chloro-2-[(2-furanylmethyl)amino]benzoic acid) (5 mg/kg).
  • furosemide 5-(aminosulphonyl)- 4-chloro-2-[(2-furanylmethyl)amino]benzoic acid)
  • the test substances are administered either directly into the femoral artery by means of a hypodermic needle or as suspension or solution by gavage into the stomach, and their effect on blood pressure and heart rate is evaluated.
  • the compounds of the present invention have a blood pressure-lowering effect in the described in vivo test with i.v. doses of about 0.003 to about 0.3 mg/kg and with oral doses of about 0.3 to about 30 mg/kg.
  • the compounds of the formula (I), and preferably of the formula (IA), and their pharmaceutically acceptable salts can be used as medicines, e.g. in the form of pharmaceutical products.
  • the pharmaceutical products can be administered enterally, such as orally, e.g. in the form of tablets, lacquered tablets, sugar-coated tablets, hard and soft gelatine capsules, solutions, emulsions or suspensions, nasally, e.g. in the form of nasal sprays, rectally, e.g. in the form of suppositories, or transdermally, e.g. in the form of ointments or patches.
  • administration is also possible parenterally, such as intramuscularly or intravenously, e.g. in the form of solutions for injection.
  • Tablets, lacquered tablets, sugar-coated tablets and hard gelatine capsules can be produced by processing the compounds of the formula (I), or preferably of the formula (IA), and their pharmaceutically acceptable salts with pharmaceutically inert inorganic or organic excipients.
  • Excipients of these types which can be used for example for tablets, sugar-coated tablets and hard gelatine capsules are lactose, maize starch or derivatives thereof, talc, stearic acid or salts thereof etc.
  • Excipients suitable for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semisolid and liquid polyols etc.
  • Excipients suitable for producing solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose etc.
  • Excipients suitable for solutions for injection are, for example, water, alcohols, polyols, glycerol, vegetable oils, bile acids, lecithin etc.
  • Excipients suitable for suppositories are, for example, natural or hardened oils, waxes, fats, semiliquid or liquid polyols etc.
  • the pharmaceutical products may in addition comprise preservatives, solubilizers, viscosity- increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, aromatizers, salts to alter the osmotic pressure, buffers, coating agents or antioxidants. They may also comprise other substances of therapeutic value.
  • the present invention further provides the use of the compounds of the formula (I), or preferably of the formula (IA), and their pharmaceutically acceptable salts in the treatment or prevention of high blood pressure, heart failure, glaucoma, myocardial infarction, renal failure restenoses and stroke.
  • the compounds of the formula (I), and preferably of the formula (IA), and their pharmaceutically acceptable salts can also be administered in combination with one or more agents having cardiovascular activity, e.g. ⁇ - and ⁇ -blockers such as phentolamine, phenoxy- benzamine, prazosin, terazosin, tolazine, atenolol, metoprolol, nadolol, propranolol, timolol, carteolol etc.; vasodilators such as hydralazine, minoxidil, diazoxide, nitroprusside, flosequinan etc.; calcium antagonists such as amrinone, bencyclan, diltiazem, fendiline, flunarizine, nicardipine, nimodipine, perhexiline, verapamil, gallopamil, nifedipine etc.; ACE inhibitors such as cilazapril
  • a daily dose appropriate for oral administration ought to be from about 3 mg to about 3 g, preferably about 10 mg to about 1 g, e.g. approximately 300 mg per adult person (70 kg), divided into preferably 1-3 single doses, which may be for example of equal size, although the stated upper limit may also be exceeded if this proves to be indicated, and children usually receive a reduced dose appropriate for their age and body weight.
  • a daily dose appropriate for oral administration ought to be from about 3 mg to about 3 g, preferably about 10 mg to about 1 g, e.g. approximately 300 mg per adult person (70 kg), divided into preferably 1-3 single doses, which may be for example of equal size, although the stated upper limit may also be exceeded if this proves to be indicated, and children usually receive a reduced dose appropriate for their age and body weight.
  • a solution of 1 mmol of "lactone" in 5 ml of dioxane is mixed with 5 ml of water and 1.1 mmol of lithium hydroxide monohydrate. After 4-6 hours, the reaction mixture is mixed with ice and 1 M aqueous citric acid solution and extracted with tert-butyl methyl ether (3x). The combined organic phases are washed with cold water and cold brine, dried with sodium sulphate and evaporated at room temperature. The residue is dissolved without delay in 8 ml of N,N-dimethylformamide and then 5 mmol of tert-butylchlorodimethylsilane and 8.8 mmol of imidazole are added.
  • the reaction mixture is evaporated - the residue is mixed with diethyl ether and water and adjusted to pH 4 with 1M aqueous citric acid solution and then the organic phase is separated off.
  • the aqueous phase is extracted again with diethyl ether (3x) - the combined organic phases are washed with brine, dried with sodium sulphate and evaporated.
  • the residue is dissolved in 3 ml of tetrahydrofuran, and 3 ml of water and 9 ml of acetic acid are successively added.
  • the reaction mixture is poured into ice-water and extracted with diethyl ether (2x) - the combined organic phases are washed with water and brine, dried with sodium sulphate and evaporated.
  • the title compound is obtained from the residue by flash chromatography (SiO 2 60F).
  • reaction mixture is stirred at -78°C and, after 5 minutes, a solution of 1 mmol of 2-[2-azido-2- (4-isopropyl-5-oxotetrahydrofuran-2-yl)ethyl]-3-methylbutyraldehyde [173154-02-4] in 1 ml of tetrahydrofuran is added at -78°C.
  • the reaction mixture is then stirred at -78°C for 15 minutes and quenched with 1M aqueous ammonium chloride solution. It is extracted with tert-butyl methyl ether (3x). The combined organic phases are washed with brine, dried with sodium sulphate and evaporated.
  • the title compound is obtained from the residue by flash chromatography (SiO 2 60F).
  • the starting materials are prepared as follows:
  • the starting material is prepared as follows:
  • the starting material is prepared as follows:
  • the starting materials are prepared as follows:
  • the starting material is prepared as described in Example 63.
  • the starting materials are prepared as follows:
  • the starting material is prepared in analogy to Example 65 a-c from (tetrahydropyran-2(S)- yl)methanol [51450-44-3].
  • the starting material is prepared in analogy to Example 65 a-c from tetrahydropyran-3(S)-ol [72886-97-6].
  • the starting material is prepared in analogy to Example 65 a-c from tetrahydropyran-3(R)-ol [100937-76-6].
  • the starting material is prepared as follows:
  • a solution of 0.095 g of 6-azido[1 ,4]dioxepane in 2 ml of ethyl acetate is mixed with 0.053 g of 10% palladium/C (50%, moist with water), and the reaction mixture is hydrogenated with the aid of a balloon at room temperature for 45 minutes.
  • the catalyst is filtered off through Hyflo. The filtrate is then employed directly in the amide coupling.
  • the starting material is prepared as follows:
  • the starting material is prepared in analogy to Example 77 a from (exo,endo)-2-oxa- bicyclo[3.1.0]hexane-6-carboxamide [89598-52-7].
  • the starting material is prepared as follows:
  • the hydrochloride is added to a stirred mixture of 40 ml of 50% strength sodium hydroxide solution and 75 ml of tert-butyl methyl ether.
  • the organic phase is separated off, dried with sodium hydroxide (solid), evaporated and distilled at 100 mbar/40°C.
  • the title compound is obtained as a pale yellowish liquid.
  • the starting material is prepared in analogy to Example 79 a-b from (exo,endo)-2- oxabicyclo[3.1.0]hexane-6-carboxylic acid [99418-15-2].
  • the starting materials are prepared as follows:
  • Example 81c The title compound is prepared in analogy to Example 81 a-b from (R)-4-benzyl-3-((S)-6- oxaspiro[2.5]octane-1-carbonyl)oxazolidin-2-one (Example 81c).
  • the starting material is prepared as follows:
  • the starting material is obtained in analogy to Example 83 from (R)-6-oxaspiro[2.5]octane-1- carboxylic acid (Example 81b).
  • the starting material is prepared as follows:
  • Example 65 a-c The title compound is prepared in analogy to Example 65 a-c from ((Z)-2- oxabicyclo[3.1.0]hex-1-yl)methanol.
  • the starting material is prepared as follows:
  • the starting materials are prepared as follows:
  • a solution of 0.9 mmol of (7exo)-7-methoxy-3-oxabicyclo[3.3.1]nonan-9-one in 5 ml of ethanol is mixed with a solution of 1.8 mmol of hydroxylamine hydrochloride in 0.5 ml of water and heated to reflux overnight.
  • the reaction mixture is concentrated and partitioned between saturated sodium carbonate solution and diethyl ether.
  • the phases are separated and the aqueous phase is extracted with diethyl ether (2x).
  • the combined organic phases are dried with sodium sulphate and evaporated.
  • the residue is dissolved in 5 ml of ethanol, and 12.8 mmol of zinc dust and 0.8 ml of glacial acetic acid are each added alternately in small portions over the course of 2 hours.
  • the internal temperature must not exceed 50 0 C during the addition.
  • the reaction mixture is stirred at room temperature for 12 hours and filtered through Hyflo, and the filter cake is washed with cold ethanol.
  • the solution is evaporated and the residue is partitioned between 4M NaOH and diethyl ether.
  • the phases are separated and the aqueous phase is extracted with diethyl ether (2x).
  • the combined organic phases are dried with sodium sulphate and evaporated.
  • the title compounds are identified on the basis of their Rf from the residue by flash chromatography (SiO 2 60F).
  • the starting material is prepared as follows:
  • Example 91 e The title compound is prepared in analogy to Example 91 a-c from (7endo)-9,9-dimethoxy-3- oxabicyclo[3.3.1]nonan-7-ol (Example 91 e).
  • the starting material is prepared as follows:
  • the starting material is prepared as follows:
  • the starting materials are prepared as follows:
  • the starting materials are prepared as follows:
  • Example 102 f The title compound is prepared in analogy to Example 102 c from methyl trans-5- hydroxytetrahydropyran-3-carboxylate (Example 102 f).
  • Example 102 c The title compound is prepared in analogy to Example 81 c from methyl cis-5-methoxytetra- hydropyran-3-carboxylate (Example 102 c).
  • the starting material is prepared as follows:
  • Example 103 c The title compound is prepared in analogy to Example 104 a-b from methyl trans-5-methoxy- tetrahydropyran-3-carboxylate (Example 103 c).
  • the starting materials are prepared as follows:
  • Example 102 a-b The title compound is prepared in analogy to Example 102 a-b from methyl cis-5-methoxy- oxepane-3-carboxylate.
  • the starting materials are prepared as follows:
  • the title compound is prepared in analogy to Example 103 a-b from methyl trans-5-methoxy- oxepane-3-carboxylate.
  • Example 106 c The title compound is prepared in analogy to Example 103 c from methyl trans-5-hydroxy- oxepane-3-carboxylate (Example 106 c).
  • the starting material is prepared as follows:
  • Example 106 b The title compound is prepared in analogy to Example 104 a-b from methyl cis-5-methoxy- oxepane-3-carboxylate (Example 106 b).
  • the starting material is prepared as follows:
  • Example 107 b The title compound is prepared in analogy to Example 104 a-b from methyl trans-5-methoxy- oxepane-3-carboxylate (Example 107 b).
  • the starting material is prepared as follows:
  • the starting material is prepared as follows:
  • the starting material is prepared as follows:
  • the starting material is prepared as follows:
  • the starting materials are prepared as follows:
  • the starting materials are prepared as follows:
  • the starting material is prepared as follows:
  • the starting material is prepared as follows:
  • the starting material is prepared as follows:
  • the starting material is prepared as follows:
  • the starting material is prepared as follows:
  • Example 77 a-b The title compound is prepared in analogy to Example 77 a-b and Example 88 from methyl (cis)-3-oxabicyclo[3.1.0]hexane-2-carboxylate.
  • the starting material is prepared as follows:
  • the title compound is prepared in analogy to Example 77 a-b from methyl difluoro- (tetra hyd ro pyra n-4-yl )acetate .
  • the title compound is prepared in analogy to Example 102 d from difluoro(tetrahydropyran-4- yl)acetic acid.
  • the starting materials are prepared as follows:
  • the starting material is prepared as follows:
  • the starting materials are prepared as follows:
  • 0°C is mixed with a solution of 12.5 ml of trifluoroacetic acid in 111 ml of dichloromethane and stirred at 0°C for 20 minutes. Then a solution of 13.2 ml of diiodomethane in 111 ml of dichloromethane is added, and the mixture is stirred at 0 0 C for 20 minutes. A solution of 22.3 g of 4-bromo-2-(3-methoxypropoxy)-1-vinylbenzene in 111 ml of dichloromethane is added, and the mixture is warmed to room temperature and stirred for 30 minutes. The reaction mixture is quenched with saturated ammonium chloride solution, and the phases are separated.
  • the starting materials are prepared as follows:
  • a solution of 210 mmol of sodium nitrite in 120 ml of water is added dropwise to a suspension of 200 mmol of 5-bromo-2-trifluoromethoxyaniline in 500 ml of ethanol and 50 ml of cone. HCI at 0 0 C.
  • the reaction mixture is stirred at 5°C for 1.5 hours.
  • the reaction mixture is slowly added dropwise to a solution of 135 ml of cone, sulphuric acid in 2.8 I of water and stirred under reflux overnight.
  • the reaction mixture is extracted with diethyl ether (3x) - the combined organic phases are washed with water and 1 M sodium bicarbonate solution and then extracted with 2N NaOH (2x).
  • the combined aqueous phases are acidified with cone.
  • HCI and extracted with diethyl ether (3x) The combined organic phases are washed with water, dried with sodium sulphate and evaporated.
  • the crude title compound is obtained from the residue.
  • the starting material is prepared as follows:
  • reaction mixture is quenched with water/brine 1 :1 and extracted with dichloromethane (2x) - the combined organic phases are washed with brine, dried with sodium sulphate and evaporated.
  • the title compound is identified by means of its Rf from the residue by flash chromatography (SiO 2 60F).
  • the starting material is prepared as follows:
  • the starting material is prepared as described in Example 78.
  • the starting material is prepared as described in Example 85.
  • the starting materials are prepared as follows:
  • the starting materials are prepared as follows:
  • the starting materials are prepared as follows:
  • Tributyltin hydride (0.36 ml) is added to a degassed solution of 0.676 g of 0- ⁇ 2-[2-tert- butoxycarbonylamine-2-isopropyl-5-oxotetrahydrofuran-2-yl)ethyl-1-[4-chloro-3-(3-methoxy- propoxy)phenyl]-3-methylbutyl imidazolecarbothioate and 0.0271 g of 2,2'-azobisiso- butyronitrile in 15 ml of toluene. The flask is placed in an oil bath preheated to 120°, and the reaction solution is stirred under reflux for 3 hours.
  • the reaction mixture is cooled to room temperature, diluted with tert- butyl methyl ether (100 ml) and washed with brine (50 ml), dried with sodium sulphate and evaporated.
  • the residue is dissolved in 20 ml of tetrahydrofuran and, after addition of 0.713 ml of H ⁇ nig's base and 0.727 g of di-tert-butyl dicarbonate, left to stand at room temperature for 12 hours.
  • the reaction solution is diluted with tert-butyl methyl ether (50 ml) and washed with 0.1 M HCI and brine, dried with sodium sulphate and evaporated.
  • the title compound is obtained as a colourless glass from the residue by flash chromatography (SiO 2 60F).
  • the starting materials are prepared as follows:

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of the general formula (I) in which the meanings of the substituents R1 and R2 are as stated in claim 1, have renin-inhibiting properties and can be used as medicines.

Description

HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS
Field of the Invention
The present invention relates to novel alkanamides, process for their preparation and the use of the compounds as medicines, especially as renin inhibitors.
Background of the Invention
Alkanamides for use as medicines are disclosed for example in EP 0678503. In relation especially to the renin inhibition, however, there is still a need for active ingredients of high potency. The priority in this is to improve the pharmacokinetic properties. These properties, which aim at better bioavailability, are for example absorption, metabolic stability, solubility or lipophilicity.
Detailed Description of the Invention
The invention therefore provides compounds of the general formula
Figure imgf000002_0001
in which
R1 is a) saturated heterocyclyl which is optionally substituted one or more times by Ci-8- alkanoyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, Ci-6alkoxy-Ci-6alkoxy, Ci-6alkoxy-Ci-6alkyl, Ci-6alkoxycarbonylamino, Ci-6alkyl, C0-6alkylcarbonylamino, Ci-6alkylcarbonyloxy, Ci-6alkylenedioxy, optionally N-mono or N,N-di-Ci-6-alkylated amino, aryl, optionally N-mono or N,N-di-Ci-6-alkylated carbamoyl, optionally esterified carboxy, cyano, C3-8cycloalkoxy, Cs-scycloalkyl-Co-ealkyl, halogen, halo-Ci-6alkoxy, halo-Ci-6alkyl, heteroaryl, unsaturated, partially saturated or saturated heterocyclyl, hydroxy, nitro, oxide or oxo which is bonded via a C atom; or b) azepanyl-, azetidinyl-, aziridinyl-, dioxanyl-, dioxepanyl-, dioxolanyl-, dithianyl-, dithiolanyl-, furanyl-, oxathianyl-, oxepanyl-, tetrahydropyranyl-, tetrahydrofuranyl-, tetra- hydrothiophenyl-, tetrahydrothiopyranyl-, thiepanyl- or bicyclic saturated heterocyclyl-d-4alkyl each of which is optionally substituted one or more times by Ci-8alkanoyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, Ci-6alkoxy-Ci-6alkoxy, Ci-6alkoxy-Ci-6alkyl, d-ealkoxycarbonylannino, Ci-6alkyl, Co-ealkylcarbonylamino, Ci-6alkylcarbonyloxy, Ci-6alkylenedioxy, optionally N-mono or N,N-di-Ci-6-alkylated amino, aryl, optionally N-mono or N,N-di-Ci-6-alkylated carbamoyl, optionally esterified carboxy, cyano, C3-8cycloalkoxy, Cs-βcycloalkyl-Co-ealkyl, halogen, halo- Ci_6alkoxy, halo-Ci_6alkyl, heteroarγl, unsaturated, partially saturated or saturated heterocyclyl, hydroxy, nitro, oxide or oxo; or c) C2-8alkynyl which is optionally substituted one or more times by Ci-8alkanoyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, Ci-6alkoxy-Ci-6alkoxy, Ci-6alkoxy-Ci-6alkyl, Ci-6alkoxycarbonylamino, Ci-6alkyl, C0-6alkylcarbonylamino, Ci-6alkylcarbonyloxy, Ci-6alkylenedioxy, optionally N-mono or N,N-di-Ci-6-alkylated amino, aryl, optionally N-mono or N,N-di-Ci-6-alkylated carbamoyl, optionally esterified carboxy, cyano, C3-8cycloalkoxy, Cs-scycloalkyl-Co-ealkyl, halogen, halo-Ci-6-alkoxy, halo-Ci-6alkyl, heteroaryl, unsaturated, partially saturated or saturated heterocyclyl, hydroxy, nitro or oxo; or
R2 is, independently of one another, 1-4 radicals selected from:
Ci-8alkanoyl, Ci-8alkanoyl-C2-4alkoxy bearing the alkanoyl group in a position higher than α, Ci-8alkanoylamino-Ci-4alkoxy, N-Ci-4alkanoylamino-Ci-4alkyl, Ci-8alkanoyloxy-Ci-4alkyl, N'-C2-8alkanoylpiperazino-Ci-4alkoxy, N'-C2-8alkanoylpiperazino-Ci-4alkyl, Ci-8alkane- sulphonyl-Ci-4alkoxy, Ci-8alkanesulphonyl-Ci-4alkyl, Ci-8alkanesulphonylamino-Ci-4alkoxy, Ci-4alkanesulphonylamino-Ci-4alkyl, Ci-8alkanesulphonyl-Ci-4(hydroxy)alkoxy, C2-8alkenyloxy, C2-8alkenyloxy-Ci-4alkoxy, C2-8alkenyloxy-Ci-4alkyl, Ci-8alkoxy, Ci-6alkoxy-Ci-6alkanoyl, Ci-4alkoxy-C2-4alkenyl, Ci-4alkoxy-C2-4alkenyloxy, Ci-4alkoxy-Ci-4alkoxy, Ci-4alkoxy- Ci-4alkoxy-Ci-4alkyl, Ci-4alkoxy-Ci-4alkyl, Ci-4alkoxycarbonyl-Ci-4alkoxy, Ci-4alkoxycarbonyl- Ci-4alkyl, Ci-βalkoxycarbonylamino-d^alkoxy, Ci-salkoxycarbonylamino-d^alkyl, Ci-8alkyl, Ci-4alkylamino, N,N-di-Ci-4alkylamino, Ci-4alkylamino-Ci-4alkoxy, N,N-di-Ci-4alkylamino- Ci-4alkoxy, Ci-4alkylamino-Ci-4alkyl, N,N-di-Ci-4alkylamino-Ci-4alkyl, N-mono- or N,N-di- Ci-4alkylcarbamoyl-Ci-4alkoxy, N-mono- or N,N-di-Ci-4alkylcarbamoyl-Ci-4alkyl, N'-Ci-4alkylpiperazino-Ci-4alkoxy, N'-Ci-4alkylpiperazino-Ci-4alkyl, Ci-4alkylthio-Ci-4alkoxy, Ci-4alkylthio-Ci-4(hydroxy)alkoxy, Ci-4alkylthio-Ci-4alkyl, amino-C2-4alkoxy, amino-Ci-4alkyl, carbamoyl-Ci-4alkoxy, carbamoyl-Ci-8alkyl, carboxy-Ci-4alkoxy, carboxy-Ci-4alkyl, cyano- Ci-4alkoxy, cyano-Ci-4alkyl, C3-8-cycloalkoxy, C3-8cycloalkoxy-Ci-4alkoxy, C3-8cycloalkoxy- Ci-4alkyl, C3-8cycloalkyl, S,S-dioxothiomorpholino-Ci-4alkoxy, S.S-dioxothiomorpholino- Ci-4alkyl, halogen, halo-Ci-4alkoxy, halo-Ci-4alkyl, halo-C2-8(hydroxy)alkoxy, hydroxy, hydroxy-C2-8alkoxy, hydroxy-C2-8alkyl, imidazolylthio-Ci-4alkoxy, imidazolylthio-Ci-4alkyl, optionally N-oxidized morpholino-Ci-4alkoxy, morpholino-Ci-4alkyl, S-oxothiomorpholino- Ci-4alkoxy, S-oxothiomorpholino-Ci-4alkyl, piperazino-Ci-4alkoxy, piperazino-Ci-4alkyl, piperidino-Ci_4alkoxy, piperidino-Ci_4alkyl, optionally partially hydrogenated pyridyl- or N-oxidopyridyl-Ci-4alkoxy, optionally partially hydrogenated pyridyl- or N-oxidopyridyl- Ci-4alkyl, optionally N-oxidized pyridylthio-Ci-4alkoxy, optionally N-oxidized pyridylthio- Ci-4alkyl, pyrimidinylthio-Ci-4alkoxy, pyrimidinylthio-Ci-4alkyl, pyrrolidino-Ci-4alkoxy, pyrrolidino-Ci-4alkyl, thiazolinylthio-Ci-4alkoxy, thiazolinylthio-Ci-4alkyl, thiazolyl-Ci-4alkoxy, thiazolylthio-Ci-4alkoxy, thiazolylthio-Ci-4alkyl, thiomorpholino-Ci-4alkoxy, thiomorpholino- Ci-4alkyl, trifluoro-Ci-salkanesulphonyl-d^alkoxy, trifluoro-Ci-8alkanesulphonylamino- Ci-4alkyl, phenyl or naphthyl which is unsubstituted or mono-, di- or trisubstituted by Ci-4alkoxy, Ci-4alkyl, Ci-4alkylamino, di-Ci-4alkylamino, halogen, hydroxy and/or trifluoro- methyl, and phenyl- or naphthyl-Ci-4alkoxy which is unsubstituted or mono-, di- or trisubstituted by Ci-4alkoxy, Ci-4alkyl, Ci-4alkylamino, di-Ci-4alkylamino, halogen, hydroxy and/or trifluoromethyl, and salts, especially pharmaceutically acceptable salts thereof; excepting compounds in which R1 is optionally substituted N-acetylpiperidin-4-yl or optionally substituted oxopiperidinyl.
The term saturated heterocyclyl refers to 3-16-membered, mono- or bicyclic saturated heterocyclic radicals having 1 to 4 nitrogen and/or 1 or 2 sulphur or oxygen atoms. Preferred radicals have 3-8 members, particularly preferably 5 or 6 members, and are monocyclic and are optionally fused to a 3-8-membered ring which may be carbocyclic or heterocyclic. A further preferred group of heterocyclic radicals are bicyclic heterocycles which have a spiro- cyclic or bridged ring. Preferred heterocyclic radicals have in each ring 1 nitrogen, oxygen or sulphur atom, 1-2 nitrogen atoms and 1-2 oxygen atoms or 1-2 nitrogen atoms and 1-2 sulphur atoms, with at least one, preferably 1-7, carbon atom(s) being present in each ring. Examples of heterocyclyl radicals are azepanyl, azetidinyl, aziridinyl, dioxanyl, [1,4]dioxepanyl, dioxolanyl, dithianyl, dithiolanyl, morpholinyl, oxathianyl, oxepanyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothio- phenyl, tetrahydrothiopyranyl, thiepanyl or thiomorpholinyl. Examples of bicyclic heterocyclyl radicals are 2,5-dioxabicyclo[4.1.0]heptanyl, 2-oxabicyclo[2.2.1]heptanyl, 2-oxa- bicyclo[4.1.OJheptanyl, 3-oxabicyclo[4.1.OJheptanyl, 7-oxabicyclo[2.2.1]heptanyl, 2-oxabicyclo[3.1.0]hexanyl, 3-oxabicyclo[3.1.0]hexanyl, 1-oxaspiro[2.5]octanyl, 6-oxaspiro[2.5]octanyl or 3-oxabicyclo[3.3.1]nonanyl.
Heterocyclyl may be unsubstituted or substituted one or more times, e.g. once or twice, by Ci-8alkanoyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, Ci-6alkoxy-Ci-6alkoxy, Ci-6alkoxy-Ci-6alkyl, Ci-6alkoxycarbonylamino, Ci-6alkyl, C0-6alkylcarbonylamino, Ci-6alkylcarbonyloxy, - A -
Ci-6alkylenedioxy, optionally N-mono or N,N-di-Ci-6-alkylated amino, aryl, optionally N-mono or N,N-di-Ci-6-alkylated carbamoyl, optionally esterified carboxy, cyano, C3-8cycloalkoxy, Cs-scycloalkyl-Co-ealkyl, halogen, halo-Ci-6alkoxy, halo-Ci-6alkyl, heteroaryl, heterocyclyl, hydroxy, nitro, oxide or oxo.
Ci-8Alkanoyl is, for example, formyl, ethanoyl, propanoyl or butanoyl.
Ci-6Alkyl may be straight-chain or branched and/or bridged and is for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl or a pentyl or hexyl group.
Ci-6Alkylamino is, for example, methylamino, ethylamino, propylamino or butylamino.
Di-Ci-6alkylamino is, for example, dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-propylamino or N-butyl-N-methylamino.
C2-6Alkenyl may be straight-chain or branched and is, for example, allyl or vinyl C2-6Alkynyl may be straight-chain or branched and is, for example, ethynyl.
Ci-6Alkoxy is, for example, methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, secondary butyloxy, tertiary butyloxy, pentyloxy or hexyloxy.
Ci-6Alkoxycarbonylamino is preferably C2-C5alkoxycarbonylamino such as ethoxycarbonyl- amino, propyloxycarbonylamino, isopropyloxycarbonylamino, butyloxycarbonylamino, isobutyloxycarbonylamino, secondary butyloxycarbonylamino or tertiary butyloxycarbonylamino.
Ci-6Alkylcarbonyloxy is, for example, acetyloxy, propionyloxy, propylcarbonyloxy, isopropyl- carbonyloxy, butylcarbonyloxy, isobutylcarbonyloxy, secondary butylcarbonyloxy, tertiary butylcarbonyloxy, pentylcarbonyloxy or hexylcarbonyloxy.
Co-βAlkylcarbonylamino is, for example, formylamino, acetylamino, propionylamino, propyl- carbonylamino, isopropylcarbonylamino, butylcarbonylamino, isobutylcarbonylamino, secondary butylcarbonylamino, tertiary butylcarbonylamino, pentylcarbonylamino or hexylcarbonylamino.
Halogen is, for example, fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.
Halo-Ci-6alkoxy is, for example, alkoxy substituted one or more times by fluorine, chlorine, bromine or iodine, including mixed, e.g. fluorine and chlorine, substitutions, with preference for perfluorinated radicals such as trifluoromethoxy. Halo-Ci_6alkyl is, for example, alkyl substituted one or more times by fluorine, chlorine, bromine or iodine, including mixed, e.g. fluorine and chlorine, substitutions, with preference for perfluorinated radicals such as trifluoromethyl.
Ci-6Alkylenedioxy is, for example, methylenedioxy, ethylenedioxy, 1,3-propylenedioxy or 1 ,2-propylenedioxy.
Optionally N-mono or N,N-di-Ci-8-alkylated carbamoyl is, for example, carbamoyl, methyl- carbamoyl, ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl or propyl- carbamoyl.
Optionally esterified carboxy is, for example, carboxy esterified with Co-6alkyl, such as carboxy or Ci-6alkoxycarbonyl.
C3-8Cycloal koxy is preferably 3-, 5- or 6-membered cycloalkoxy such as cyclopropyloxy, cyclopentyloxy and cyclohexyloxy.
C3-8Cycloal kyl-C0-6alkyl is preferably 3-, 5- or 6-membered cycloalkyl such as cyclopropyl, cyclopropylmethyl, cyclopentyl and cyclohexyl.
Cyano-Ci-4alkoxy is, for example, cyanomethoxy, 2-cyanoethoxy, 2- or 3-cyanopropyloxy or 4-cya no butyl oxy, especially cyanomethoxy.
Cyano-Ci-4alkyl is, for example, cyanomethyl, 2-cyanoethyl, 2- or 3-cyanopropyl, 2-cyano- 2-methylpropyl or 4-cyanobutyl, especially cyanomethyl.
N,N-Di-Ci-4alkylamino is, for example, dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-propylamino or N-butyl-N-methylamino.
N,N-Di-Ci-4alkylamino-Ci-4alkoxy is 2-dimethylaminoethoxy, 3-dimethylaminopropyloxy, 4-dimethylaminobutyloxy, 2-diethylaminoethoxy, 2-(N-methyl-N-ethylamino)ethoxy or 2-(N-butyl-N-methylamino)ethoxy.
N,N-Di-Ci-4alkylamino-Ci-4alkyl is, for example, 2-dimethylaminoethyl, 3-dimethylamino- propyl, 4-dimethylaminobutyl, 2-diethylaminoethyl, 2-(N-methyl-N-ethylamino)ethyl or 2-(N-butyl-N-methylamino)ethyl.
N,N-Di-Ci-4alkylcarbamoyl-Ci-4alkoxy is, for example, methyl- or dimethylcarbamoyl- Ci-4alkoxy such as N-methyl-, N-butyl- or N,N-dimethylcarbamoylmethoxy, 2-(N- methylcarbamoyl)ethoxy, 2-(N-butylcarbamoyl)ethoxy, 2-(N,N-dimethylcarbamoyl)ethoxy, 3-(N-methylcarbamoyl)propyloxy, 3-(N-butylcarbamoyl)propyloxy, 3-(N,N-dimethyl- carbamoyl)propyloxy or 4-(N-methylcarbamoyl)butyloxy, 4-(N-butylcarbamoyl)butyloxy or 4-(N,N-dimethylcarbamoyl)butyloxy, especially N-methyl-, N-butyl- or N1N- dimethylcarbamoylmethoxy.
N.N-Di-Ci^alkylcarbamoyl-Ci^alkyl is, for example, 2-dimethylcarbamoylethyl, 3-dimethyl- carbamoylpropyl, 2-dimethylcarbamoylpropyl, 2-(dimethylcarbamoyl)-2-methylpropyl or 2-(dimethylcarbamoyl)butyl.
Optionally partially hydrogenated pyridyl- or N-oxidopyridyl-Ci-4alkoxy is, for example, pyridyl- or N-oxidopyridylmethoxy, 2-pyridylethoxy, 2- or 3-pyridylpropyloxy or 4-pyridylbutyloxy, especially 3- or 4-pyridylmethoxy.
Optionally partially hydrogenated pyridyl- or N-oxidopyridyl-Ci-4alkyl is, for example, pyridyl- or N-oxidopyridylmethyl, 2-pyridylethyl, 2- or 3-pyridylpropyl or 4-pyridyl butyl, especially 3- or 4-pyridyl methyl.
Morpholino-Ci-4alkoxy may be N-oxidized and is, for example, 1-morpholinoethoxy, 3-morpholinopropyloxy or 1-(morpholino-2-methyl)propyloxy.
Morpholino-Ci-4alkyl may be N-oxidized and is, for example, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl or 1- or 2-(4-morpholino)butyl.
Piperazino-Ci-4alkyl is, for example, piperazinomethyl, 2-piperazinoethyl or 3-piperazinopropyl.
Piperidino-Ci-4alkoxy is, for example, piperidinomethoxy, 2-piperidinoethoxy or 3-piperidinopropyloxy.
Piperidino-Ci-4alkyl is, for example, piperidinomethyl, 2-piperidinoethyl or 3-piperidinopropyl. Pyrrolidino-C2-4alkoxy is, for example, 2-pyrrolidinoethoxy or 3-pyrrolidinopropyloxy.
Pyrrolidino-Ci-4alkyl is, for example, pyrrolidinomethyl, 2-pyrrolidinoethyl or 3- pyrrolidinopropyl.
S-Oxothiomorpholino-Ci-4alkyl is, for example, S-oxothiomorpholinomethyl or 2-(S- oxothiomorpholino)ethyl.
Thiazolyl-Ci-4alkoxy is, for example, thiazolylmethoxy, 2-thiazolylethoxy or 3-thiazolylpropyloxy.
Thiomorpholino-Ci-4alkyl or S,S-dioxothiomorpholino-Ci-4alkyl is, for example, thiomorpholino-Ci-4alkyl such as -methyl or -ethyl, or S,S-dioxothiomorpholino-Ci-4alkyl such as -methyl or -ethyl. Depending on the presence of asymmetric carbon atoms, the compounds of the invention may be in the form of mixtures of isomers, specifically as racemates, or in the form of pure isomers, specifically of optical antipodes. The invention includes all these forms. Mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates can be fractionated by conventional methods, e.g. by column chromatography, thin-layer chromatography, HPLC and the like.
Salts of compounds with salt-forming groups are in particular acid addition salts, salts with bases or, if a plurality of salt-forming groups is present, optionally also mixed salts or inner salts.
Salts are primarily the pharmaceutically acceptable or non-toxic salts of compounds of the formula (I). Such salts are formed for example by compounds of the formula (I) having an acidic group, e.g. a carboxy or sulpho group, and are for example their salts with suitable bases, such as non-toxic metal salts derived from metals of group Ia, Ib, Na and Nb of the Periodic Table of the Elements, e.g. alkali metal, in particular lithium, sodium or potassium, salts, alkaline earth metal salts, for example magnesium or calcium salts, furthermore zinc salts or ammonium salts, also salts formed with organic amines such as optionally hydroxy- substituted mono-, di- or trialkylamines, especially mono-, di- or tri-lower-alkylamines, or with quaternary ammonium bases, e.g. methyl-, ethyl-, diethyl- or triethylamine, mono-, bis- or tris(2-hydroxy-lower-alkyl)amines such as ethanol-, diethanol- or triethanolamine, tris(hydroxymethyl)methylamine or 2-hydroxy-tertiary-butylamine, N.N-di-lower-alkyl- N-(hydroxy-lower-alkyl)amine, such as N,N-dimethyl-N-(2-hydroxyethyl)amine, or N-methyl- D-glucamine, or quaternary ammonium hydroxides such as tetrabutylammonium hydroxide. The compounds of the formula I having a basic group, e.g. an amino group, can form acid addition salts, e.g. with suitable inorganic acids, e.g. hydrohalic acid such as hydrochloric acid, hydrobromic acid, sulphuric acid with replacement of one or both protons, phosphoric acid with replacement of one or more protons, e.g. orthophosphoric acid or metaphosphoric acid, or pyrophosphoric acid with replacement of one or more protons, or with organic car boxy lie, sulphonic or phosphonic acids or N-substituted sulphamic acids, e.g. acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methyl maleic acid, fumaric acid, malic acid, tartaric acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2- phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid, isonicotinic acid, furthermore amino acids such as, for example, the α-amino acids mentioned hereinbelow, and methanesulphonic acid, ethanesulphonic acid, 2-hydroxyethanesul phonic acid, ethane- 1 ,2-disulphonic acid, benzenesulphonic acid, 4-toluenesulphonic acid, naphthalene- 2-sulphonic acid, 2- or 3-phosphoglycerate, glucose 6-phosphate, N-cyclohexylsulphamic acid (to form cyclamates) or with other acidic organic compounds such as ascorbic acid. Compounds of the formula (I) having acidic and basic groups may also form inner salts.
Pharmaceutically unsuitable salts may also be used for isolation and purification.
The compounds of the formula (I) also include compounds in which one or more atoms are replaced by their stable, non-radioactive isotopes; for example a hydrogen atom by deuterium.
Prodrug derivatives of the compounds described herein are derivatives thereof which on in vivo use liberate the original compound by a chemical or physiological process. A prodrug may for example be converted into the original compound when a physiological pH is reached or by enzymatic conversion. Possible examples of prodrug derivatives are esters of freely available carboxylic acids, S- and O-acyl derivatives of thiols, alcohols or phenols, the acyl group being defined as above. Preferred derivatives are pharmaceutically acceptable ester derivatives which are converted by solvolysis in physiological medium into the original carboxylic acid, such as, for example, lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or disubstituted lower alkyl esters such as lower ω-(amino, mono- or dialkylamino, carboxy, lower alkoxycarbonyl) - alkyl esters or such as lower α-(alkanoyloxy, alkoxycarbonyl or dialkylaminocarbonyl) - alkyl esters; conventionally, pivaloyloxymethyl esters and similar esters are used as such.
Because of the close relationship between a free compound, a prodrug derivative and a salt compound, a particular compound in this invention also includes its prodrug derivative and salt form, where this is possible and appropriate.
The groups of compounds mentioned hereinafter are not to be regarded as closed; on the contrary, it is possible for parts of these groups of compounds to be interchanged or replaced by the definitions given above, or omitted, in a worthwhile manner, e.g. to replace general by more specific definitions. Further preferred compounds have the general formula
Figure imgf000010_0001
in which
R1 has the meaning indicated for the compound of the formula (I) and
R' and R", independently of one another, have the meanings indicated for R2 for the compound of the formula (I).
R2 is preferably, independently of one another, 1-4 radicals selected from: Ci- 8alkanoylamino-Ci-4alkoxy, N-Ci-4alkanoylamino-Ci-4alkyl, Ci-8alkoxy, Ci-4alkoxy-Ci-4alkoxy, Ci-4alkoxy-Ci-4alkoxy-Ci-4alkyl, Ci-4alkoxy-Ci-4alkyl, Ci-salkoxycarbonylamino-d^alkoxy, Ci-salkoxycarbonylamino-Ci^alkyl, Ci-8alkyl, halogen, trifluoromethoxy and trifluoromethyl. R2 is particularly preferably, independently of one another, 1-4 radicals selected from: Ci-8alkoxy, Ci-4alkoxy-Ci-4alkoxy, Ci-4alkoxy-Ci-4alkoxy-Ci-4alkyl, Ci-4alkoxy-Ci-4alkyl, Ci-8alkyl, halogen, trifluoromethoxy and trifluoromethyl.
R1 is preferably optionally substituted C2-6alkynyl, optionally substituted saturated hetero- cyclyl bonded via a C atom or optionally substituted saturated bicyclic heterocyclyl-C0-4alkyl. R1 is particularly preferably optionally substituted C2-6alkynyl, optionally substituted saturated bicyclic heterocyclyl-C0-4alkyl, optionally substituted pyrrolidinyl, Ci-6-alkylated or C3-8. cycloalkyl-Co-6-alkylated piperidine, optionally substituted tetrahydrofuranyl, optionally substituted tetrahydrofuranylmethyl, optionally substituted tetrahydropyranyl or optionally substituted tetrahydropyranyl methyl.
R1 is particularly preferably also optionally substituted tetrahydrofuranylmethyl, optionally substituted tetrahydropyranyl methyl, optionally substituted saturated heterocyclyl which is bonded via a C atom or optionally substituted saturated bicyclic heterocyclyl-C0-4alkyl, where the heterocyclyl radical in each case comprises an oxygen atom as heteroatom. Also particularly preferred are compounds of the general formula (I') where
R' is
Figure imgf000011_0001
N-Ci-4alkanoylamino-Ci-4alkyl, Ci-4alkoxy-Ci-4alkoxy-
Ci-4alkyl, Ci-4alkoxy-Ci-4alkoxy, Ci-4alkoxy-Ci-4alkyl, Ci-salkoxycarbonylamino-d^alkoxy or
Ci-salkoxycarbonylamino-Ci^alkyl; and
R" is Ci-8alkanoyl, Ci-8alkoxy, Ci-8alkyl, difluoroethyl, halogen, trifluoromethoxy or trifluoromethyl.
Also particularly preferred are compounds of the general formula (I1) where
R' is Ci-4alkoxy-Ci-4alkoxy;
R" is fluorine; and
R1 is optionally substituted tetrahydrofuranylmethyl, optionally substituted tetrahydropyranyl- methyl, optionally substituted saturated heterocyclyl which is bonded via a C atom or optionally substituted saturated bicyclic heterocyclyl-Co^alkyl, where the heterocyclyl radical preferably in each case comprises an oxygen atom as heteroatom.
Particularly preferred in each case are those compounds of the formula I, in which at least one, for example one, two, three or, preferably, all four asymmetric C atoms of the main chain have the stereochemistry shown in formula IA ("S" in each case), where the substituents each have the meanings indicated above, and their pharmaceutically acceptable salts.
Figure imgf000011_0002
The compounds of the formula (I) and formula (IA) can be prepared in an analogous manner to the preparation process disclosed in the literature (see WO 2002008172 and
WO 2002002508 and literature cited therein) (scheme). Further preparation processes are described for example in EP 678503, WO 01/09079, WO 01/09083, WO 02/02487,
WO 02/02500, WO 02/092828 and in Helvetica Chemica Acta 86 (2003), 2848-2870 and literature cited therein. ethanolamine
Figure imgf000012_0001
chloro enamine, R1NH2
Figure imgf000012_0003
Figure imgf000012_0002
Details of the specific preparation variants can be found in the examples.
The compounds of the formula (I) can also be prepared in optically pure form. Separation into antipodes can take place by methods known per se, either preferably at an early stage in the synthesis by salt formation with an optically active acid such as, for example, (+)- or (-)-mandelic acid and separation of the diastereomeric salts by fractional crystallization or preferably at a rather late stage by derivatizing with a chiral auxiliary component such as, for example, (+)- or (-)-camphanoyl chloride, and separation of the diastereomeric products by chromatography and/or crystallization and subsequent cleavage of the linkage to the chiral auxiliary. The pure diastereomeric salts and derivatives can be analysed to determine the absolute configuration of the contained piperidine by conventional spectroscopic methods, with X-ray spectroscopy on single crystals representing a particularly suitable method.
The compounds of the formula (I), and of the formula (IA), and their pharmaceutically acceptable salts have an inhibitory effect on the natural enzyme renin. The latter passes from the kidneys into the blood and there brings about the cleavage of angiotensinogen to form the decapeptide angiotensin I which is then cleaved in the lung, the kidneys and other organs to the octapeptide angiotensin II. Angiotensin Il raises the blood pressure both directly by arterial constriction, and indirectly by releasing the hormone aldosterone, which retains sodium ions, from the adrenals, which is associated with an increase in the extracellular fluid volume. This increase is attributable to the effect of angiotensin Il itself or of the heptapeptide angiotensin III formed therefrom as cleavage product. Inhibitors of the enzymatic activity of renin bring about a reduction in the formation of angiotensin I and, as a consequence thereof, the formation of a smaller amount of angiotensin II. The reduced concentration of this active peptide hormone is the direct cause of the blood pressure-lowering effect of renin inhibitors.
The effect of renin inhibitors is detected inter alia experimentally by means of in vitro tests where the reduction in the formation of angiotensin I is measured in various systems (human plasma, purified human renin together with synthetic or natural renin substrate). The following in vitro test of Nussberger et al. (1987) J. Cardiovascular Pharmacol., Vol. 9, pp. 39-44, is used inter alia. This test measures the formation of angiotensin I in human plasma. The amount of angiotensin I formed is determined in a subsequent radioimmunoassay. The effect of inhibitors on the formation of angiotensin I is tested in this system by adding various concentrations of these substances. The IC50 is defined as the concentration of the particular inhibitor which reduces the formation of angiotensin I by 50%. The compounds of the present invention show inhibitory effects in the in vitro systems at minimal concentrations of about 10~6 to about 10~10 mol/l.
Renin inhibitors bring about a fall in blood pressure in salt-depleted animals. Human renin differs from renin of other species. Inhibitors of human renin are tested using primates (marmosets, Callithrix jacchus) because human renin and primate renin are substantially homologous in the enzymatically active region. The following in vivo test is employed inter alia: the test compounds are tested on normotensive marmosets of both sexes with a body weight of about 350 g, which are conscious, unrestrained and in their normal cages. Blood pressure and heart rate are measured with a catheter in the descending aorta and are recorded radiometrically. Endogenous release of renin is stimulated by combining a low-salt diet for 1 week with a single intramuscular injection of furosemide (5-(aminosulphonyl)- 4-chloro-2-[(2-furanylmethyl)amino]benzoic acid) (5 mg/kg). 16 hours after the furosemide injection, the test substances are administered either directly into the femoral artery by means of a hypodermic needle or as suspension or solution by gavage into the stomach, and their effect on blood pressure and heart rate is evaluated. The compounds of the present invention have a blood pressure-lowering effect in the described in vivo test with i.v. doses of about 0.003 to about 0.3 mg/kg and with oral doses of about 0.3 to about 30 mg/kg.
The compounds of the formula (I), and preferably of the formula (IA), and their pharmaceutically acceptable salts can be used as medicines, e.g. in the form of pharmaceutical products. The pharmaceutical products can be administered enterally, such as orally, e.g. in the form of tablets, lacquered tablets, sugar-coated tablets, hard and soft gelatine capsules, solutions, emulsions or suspensions, nasally, e.g. in the form of nasal sprays, rectally, e.g. in the form of suppositories, or transdermally, e.g. in the form of ointments or patches. However, administration is also possible parenterally, such as intramuscularly or intravenously, e.g. in the form of solutions for injection.
Tablets, lacquered tablets, sugar-coated tablets and hard gelatine capsules can be produced by processing the compounds of the formula (I), or preferably of the formula (IA), and their pharmaceutically acceptable salts with pharmaceutically inert inorganic or organic excipients.
Excipients of these types which can be used for example for tablets, sugar-coated tablets and hard gelatine capsules are lactose, maize starch or derivatives thereof, talc, stearic acid or salts thereof etc.
Excipients suitable for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semisolid and liquid polyols etc.
Excipients suitable for producing solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose etc.
Excipients suitable for solutions for injection are, for example, water, alcohols, polyols, glycerol, vegetable oils, bile acids, lecithin etc.
Excipients suitable for suppositories are, for example, natural or hardened oils, waxes, fats, semiliquid or liquid polyols etc.
The pharmaceutical products may in addition comprise preservatives, solubilizers, viscosity- increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, aromatizers, salts to alter the osmotic pressure, buffers, coating agents or antioxidants. They may also comprise other substances of therapeutic value.
The present invention further provides the use of the compounds of the formula (I), or preferably of the formula (IA), and their pharmaceutically acceptable salts in the treatment or prevention of high blood pressure, heart failure, glaucoma, myocardial infarction, renal failure restenoses and stroke.
The compounds of the formula (I), and preferably of the formula (IA), and their pharmaceutically acceptable salts can also be administered in combination with one or more agents having cardiovascular activity, e.g. α- and β-blockers such as phentolamine, phenoxy- benzamine, prazosin, terazosin, tolazine, atenolol, metoprolol, nadolol, propranolol, timolol, carteolol etc.; vasodilators such as hydralazine, minoxidil, diazoxide, nitroprusside, flosequinan etc.; calcium antagonists such as amrinone, bencyclan, diltiazem, fendiline, flunarizine, nicardipine, nimodipine, perhexiline, verapamil, gallopamil, nifedipine etc.; ACE inhibitors such as cilazapril, captopril, enalapril, lisinopril etc.; potassium activators such as pinacidil; antiserotoninergics such as ketanserine; thromboxane synthetase inhibitors; neutral endopeptidase inhibitors (NEP inhibitors); angiotensin Il antagonists; and diuretics such as hydrochlorothiazide, chlorothiazide, acetazolamide, amiloride, bumetanide, benzthiazide, ethacrynic acid, furosemide, indacrinone, metolazone, spironolactone, triamterene, chlorthalidone etc.; sympatholytics such as methyldopa, clonidine, guanabenz, reserpine; and other agents suitable for the treatment of high blood pressure, heart failure or vascular disorders associated with diabetes or renal disorders such as acute or chronic renal failure in humans and animals. Such combinations can be used separately or in products which comprise a plurality of components.
Further substances which can be used in combination with the compounds of the formulae (I) or (IA) are the compounds of classes (i) to (ix) on page 1 of WO 02/40007 (and the preferences and examples detailed further therein) and the substances mentioned on pages 20 and 21 of WO 03/027091.
The dosage may vary within wide limits and must of course be adapted to the individual circumstances in each individual case. In general, a daily dose appropriate for oral administration ought to be from about 3 mg to about 3 g, preferably about 10 mg to about 1 g, e.g. approximately 300 mg per adult person (70 kg), divided into preferably 1-3 single doses, which may be for example of equal size, although the stated upper limit may also be exceeded if this proves to be indicated, and children usually receive a reduced dose appropriate for their age and body weight. Examples
The following examples illustrate the present invention. All temperatures are stated in degrees Celsius and pressures in mbar. Unless mentioned otherwise, the reactions take place at room temperature. The abbreviation "Rf = xx (A)" means for example that the Rf is found in solvent system A to be xx. The ratio of amounts of solvents to one another is always stated in parts by volume. Chemical names for final products and intermediates have been generated on the basis of the chemical structural formulae with the aid of the AutoNom 2000 (Automatic Nomenclature) program. Unless mentioned otherwise, the absolute stereochemistry of all four asymmetric C atoms in the main chain is "S" in each case.
HPLC gradients on Hypersil BDS C-18 (5 urn); column: 4 x 125 mm
I 90% water*/10% acetonitrile* to 0% water*/100% acetonitrile* in 5 minutes + 2.5 minutes (1.5 ml/min)
II 95% water*/5% acetonitrile* to 0% water*/100% acetonitrile* in 40 minutes (0.8 ml/min)
* contains 0.1% trifluoroacetic acid
The following abbreviations are used:
M. p. melting point (temperature)
Rf ratio of distance migrated by a substance to the distance of the solvent front from the starting point in thin-layer chromatography Rt retention time of a substance in HPLC (in minutes)
General Method A: (azide reduction)
A solution of 1 mmol of "azide derivative" in 10-20 ml of ethanol and ethanolamine (1 equiv) is hydrogenated in the presence of 200-400 mg of Pd/C 10% (moist) at 00C for 1-3 hours. The reaction mixture is clarified by filtration and the catalyst is washed with ethanol. The filtrate is evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
General Method B: (lactone amidation I)
A mixture of 1 mmol of "lactone", "amine" (10-30 equiv.) and 2-hydroxypyridine (1 equiv.) is stirred at 65°C for 2-24 hours. The reaction mixture is cooled to room temperature, evaporated, mixed with 1 M aqueous sodium bicarbonate solution and extracted with tert- butyl methyl ether (2x). The combined organic phases are washed with water and brine, dried with sodium sulphate and evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
General Method C: (lactone amidation II)
A solution of 1.2 mmol of "amine" in 1-2 ml of toluene is added to a solution of 1.1 mmol of trimethylaluminium solution (2M in heptane) at -78°C. The reaction mixture is warmed to room temperature, stirred for a further 30-60 minutes and then evaporated. A solution of 1 mmol of "lactone" in 2 ml of toluene is added to the residue, and the mixture is stirred at 800C for 2-4 hours. The reaction mixture is cooled to room temperature and, after addition of 10 ml of 1 N HCI, stirred for 30 minutes. The reaction mixture is diluted with brine and extracted with toluene (2x) - the combined organic phases are dried with sodium sulphate and evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
General Method D: (desilylation)
1.5 mmol of tetrabutylammonium fluoride solution (1M in tetrahydrofuran) are added to a solution of 1 mmol of "silyl ether" in 10-15 ml of tetrahydrofuran at 0°C. The reaction mixture is stirred at room temperature for 2-4 hours, poured into 1 M aqueous sodium bicarbonate solution and extracted with tert-butyl methyl ether (2x). The combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
General Method E: (chloro enamine coupling)
1.2-1.8 mmol of (1-chloro-2-methylpropenyl)dimethylamine (chloro enamine) are added to a solution of 1 mmol of "acid" in 10 ml of dichloromethane at 0°C. After 2-4 hours, the reaction mixture is evaporated and the residue is dissolved in 6 ml of dichloromethane - this solution is added dropwise to the solution of 1.25 mmol of "amine" and 1.1 mmol of triethylamine in 6 ml of dichloromethane at 0°C over the course of 2-10 minutes. The reaction mixture is stirred at room temperature for 1-2 hours, poured into water and extracted with tert-butyl methyl ether (2x). The combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F). General Method F: (lactone opening/silylation)
A solution of 1 mmol of "lactone" in 5 ml of dioxane is mixed with 5 ml of water and 1.1 mmol of lithium hydroxide monohydrate. After 4-6 hours, the reaction mixture is mixed with ice and 1 M aqueous citric acid solution and extracted with tert-butyl methyl ether (3x). The combined organic phases are washed with cold water and cold brine, dried with sodium sulphate and evaporated at room temperature. The residue is dissolved without delay in 8 ml of N,N-dimethylformamide and then 5 mmol of tert-butylchlorodimethylsilane and 8.8 mmol of imidazole are added. After 10-20 hours, the reaction mixture is evaporated - the residue is mixed with diethyl ether and water and adjusted to pH 4 with 1M aqueous citric acid solution and then the organic phase is separated off. The aqueous phase is extracted again with diethyl ether (3x) - the combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The residue is dissolved in 3 ml of tetrahydrofuran, and 3 ml of water and 9 ml of acetic acid are successively added. After 3-4 hours, the reaction mixture is poured into ice-water and extracted with diethyl ether (2x) - the combined organic phases are washed with water and brine, dried with sodium sulphate and evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
General Method G: (Grignard reaction)
A solution of 1.33 mmol of "aryl bromide" in 2.70 ml of tetrahydrofuran is cooled to -78°C, and 2 mmol of N-methylmorpholine are added. Then 1.33 mmol of butyllithium solution (1.6M in hexane) are added at -78°C. The reaction mixture is stirred at -78°C for 5 minutes, and 2 mmol of magnesium bromide solution (0.3M, freshly prepared from 2 mmol of Mg turnings and 2 mmol of 1,2-dibromoethane in 6.67 ml of tetrahydrofuran at 600C) are added. The reaction mixture is stirred at -78°C and, after 5 minutes, a solution of 1 mmol of 2-[2-azido-2- (4-isopropyl-5-oxotetrahydrofuran-2-yl)ethyl]-3-methylbutyraldehyde [173154-02-4] in 1 ml of tetrahydrofuran is added at -78°C. The reaction mixture is then stirred at -78°C for 15 minutes and quenched with 1M aqueous ammonium chloride solution. It is extracted with tert-butyl methyl ether (3x). The combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
General Method H: (alcohol methoxyacetylation)
2.6 mmol of pyridine, 2.4 mmol of methoxyacetyl chloride and 0.1 mmol of 4-dimethylamino- pyridine are successively added to a solution of 1 mmol of "alcohol" in 13.5 ml of toluene at 0°C. The ice bath is removed and the reaction mixture is stirred at room temperature for 2 hours. The reaction mixture is poured into 0.5M HCI and then the organic phase is separated off. The aqueous phase is extracted again with diethyl ether (3x) - the combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
General Method I: (azide and methoxyacetoxy reduction) A solution of 1 mmol of "azide methoxyacetoxy derivative" in 25 ml of ethanol and ethanolamine (1 mmol) is hydrogenated in the presence of 600 mg of Pd/C 10% (dry) at room temperature for 2-5 hours. The reaction mixture is clarified by filtration and the catalyst is washed with ethanol. The filtrate is evaporated. The residue is treated with 1M sodium bicarbonate solution and extracted with tert-butyl methyl ether (3x) - the combined organic phases are dried with sodium sulphate and evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
General Method J: (Boc protection of amine)
2 mmol of N,N-diisopropylethylamine and 2 mmol of di-tert-butyl dicarbonate are successively added to a solution of 1 mmol of "amine" in 22 ml of dichloromethane at 00C. The reaction mixture is warmed to room temperature and stirred at room temperature overnight. The reaction mixture is poured into water and then the organic phase is separated off. The aqueous phase is again extracted with dichloromethane (2x) - the combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
General Method K: (Boc deprotection of amine)
50 mmol of trifluoroacetic acid are added to a solution of 1 mmol of "amine" in 20 ml of dichloromethane at 0°C. The reaction mixture is stirred at 0°C for 1-3 hours. The reaction mixture is neutralized with 1 M sodium bicarbonate solution, and the aqueous phase is extracted with tert-butyl methyl ether (3x) - the combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
General Method L: (phenol alkylation)
A solution of 1 mmol of "phenol" in 2 ml of dimethylformamide is mixed with 1.5 mmol of potassium carbonate and 1.1 mmol of 1-chloro-3-methoxypropane. The reaction mixture is stirred at 100°C for 11 hours. The reaction mixture is filtered and evaporated. The residue is partitioned between ethyl acetate and water/brine 9:1. The phases are separated, the aqueous phase is extracted with ethyl acetate (2x) - the combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
Example 1 :
5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid prop-2-vnylamide
Firstly 1.5 ml of methanol and 0.35 ml of cone, ammonia 25% and then 0.228 g of triphenyl- phosphine are added to a mixture of 0.300 g of 5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy- 3-(3-methoxypropoxy)benzyl]-8-methylnonanoic acid prop-2-ynylamide in 1.6 ml of tetra- hydrofuran and 0.38 ml of water at room temperature. After 65 hours, the reaction mixture is poured into water and extracted with tert-butyl methyl ether (3x) - the combined organic phases are washed successively with water and brine, dried with sodium sulphate and evaporated. The title compound is obtained as a colourless oil from the residue by flash chromatography (SiO2 60F). Rf = 0.19 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.73 (gradient I).
The starting materials are prepared as follows:
a) 5-Azido-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid prop-2-vnylamide
0.42 g of 5-azido-4-(tert-butyldimethylsilanyloxy)-2-isopropyl-7-[4-methoxy-3-(3-methoxy- propoxy)benzyl]-8-methylnonanoic acid prop-2-ynylamide is reacted in analogy to Method D. The title compound is obtained as a yellowish oil. Rf = 0.24 (EtOAc/heptane 1 :1); Rt = 4.85 (gradient I).
b) 5-Azido-4-(tert-butyldimethylsilanyloxy)-2-isopropyl-7-r4-methoxy-3-(3-methoxy- propoxy)benzyll-8-methylnonanoic acid prop-2-vnylamide
0.40 g of 5-azido-4-(tert-butyldimethylsilanyloxy)-2-isopropyl-7-[4-methoxy-3-(3-methoxy- propoxy)benzyl]-8-methylnonanoic acid and 0.055 ml of prop-2-ynylamine are reacted in analogy to Method E. The crude title compound is employed in the next stage. Rt = 6.44 (gradient I). c) 5-Azido-4-(tert-butyldimethylsilanyloxy)-2-isopropyl-7-r4-methoxy-3-(3-methoxy- propoxy)benzyll-8-nnethylnonanoic acid
0.933 g of 5-{1-azido-3-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl}- 3-isopropyldihydrofuran-2-one [324763-46-4] is reacted in analogy to Method F. The title compound is obtained as a yellowish oil. Rf = 0.40 (EtOAc/heptane 1 :1); Rt = 6.54 (gradient I).
Example 2:
5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1-methylpiperidin-4-yl)amide
0.499 g of 5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]- 8-methylnonanoic acid (1-methylpiperidin-4-yl)amide is reacted in analogy to Method A. The title compound is obtained as a yellowish oil. Rf = 0.12 (dichloromethane/methanol/conc. ammonia 25% 80:10:1); Rt = 3.18 (gradient I).
The starting material is prepared as follows:
a) 5-Azido-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1-methylpiperidin-4-yl)amide
0.466 g of 5-{1-azido-3-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl}-3- isopropyldihydrofuran-2-one [324763-46-4] and 1.165 g of 1-methylpiperidin-4-ylamine are reacted in analogy to Method B. The title compound is obtained as a colourless oil. Rt = 4.13 (gradient I).
Example 3:
5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acidpiperidin-4-ylamide dihydrochloride
0.712 g of benzyl 4-{5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)- benzyl]-8-methylnonanoylamino}piperidine-1-carboxylate is reacted in analogy to Method A. The crude product is dissolved in a little tert-butanol and, after addition of 2 drops of 4N HCI/dioxane, frozen in liquid nitrogen and lyophilized under high vacuum overnight. The title compound is obtained from the residue as a white solid. Rf = 0.17 (dichloromethane/methanol/conc. ammonia 25% 40:10:1); Rt = 3.11 (gradient I). The starting material is prepared as follows:
a) Benzyl 4-(5-azido-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8- methylnonanoylaminolpiperidine-i-carboxylate
0.466 g of 5-{1-azido-3-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl}-3- isopropyldihydrofuran-2-one [324763-46-4], 1.21 g of benzyl 4-aminopiperidine-1-carboxylate and 1.05 ml of triethylamine are reacted in analogy to Method B. The title compound is obtained as a yellowish oil. Rt = 5.34 (gradient I).
Example 4:
5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acidpyrrolidin-3(R)-ylamide dihydrochloride
0.607 g of 5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8- methylnonanoic acidpyrrolidin-3(R)-ylamide is reacted in analogy to Method A. The chroma- tographed product is dissolved in 10 ml of dichloromethane, dried with sodium sulphate and filtered, and 1 ml of 4N HCI/dioxane is added and evaporated. The residue is dissolved in 2 ml of tert-butanol, frozen in liquid nitrogen and lyophilized under high vacuum overnight. The title compound is obtained as a white solid from the residue. Rf = 0.08 (dichloromethane/ methanol/conc. ammonia 25% 40:20:1); Rt = 3.12 (gradient I).
The starting material is prepared as follows:
a) 5-Azido-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acidpyrrolidin-3(R)-ylamide
A solution of 0.83 g of tert-butyl 3(R)-{5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3- methoxypropoxy)benzyl]-8-methylnonanoylamino}pyrrolidine-1-carboxylate in 12 ml of 4N HCI/dioxane is stirred at 00C for 1 hour and then evaporated. The title compound is obtained as a yellow oil from the residue by flash chromatography (SiO2 60F). Rf = 0.25 (dichloro- methane/methanol/conc. ammonia 25% 40:10:1); Rt = 4.03 (gradient I).
The following compounds are prepared in an analogous manner to the process described in Examples 1-4: Examples
5 5-Amino-4-hvdroxy-2-isopropyl-7-r4-nnethoxy-3-(3-nnethoxypropoxy)benzyll-8-nnethyl- nonanoic acid (tetrahvdropyran-4-yl)amide yellowish oil; Rf = 0.37 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.52 (gradient I).
6 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1-methylpyrrolidin-3(S)-yl)amide dihydrochloride white solid; Rf = 0.21 (dichloromethane/methanol/conc. ammonia 25% 40:20:1); Rt = 3.18 (gradient I).
7 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1-methylpyrrolidin-3(R)-yl)amide dihydrochloride white solid; Rf = 0.17 (dichloromethane/methanol/conc. ammonia 25% 40:20:1); Rt = 3.14 (gradient I).
8 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid pyrrolidin-3(S)-ylamide dihydrochloride white solid; Rf = 0.09 (dichloromethane/methanol/conc. ammonia 25% 40:20:1); Rt = 3.10 (gradient I).
9 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1 ,1-dimethylprop-2-vnyl)amide
10 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid but-2-ynylamide
11 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid azetidin-3-ylamide dihydrochloride
12 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1-methylazetidin-3-yl)amide dihydrochloride
13 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (azetidin-3-ylmethyl)amide colourless glass; Rf = 0.20 (dichloromethane/methanol/conc. ammonia 25% 40:10:1); Rt = 3.14 (gradient I).
14 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1-methylazetidin-3-ylmethyl)amide dihydrochloride
21 5-Amino-4-hvdroxy-2-isopropyl-7-r3-(3-methoxypropoxy)-4-methylbenzyll-8-methyl- nonanoic acid (tetrahydropyran-4-yl)amide beige oil; Rf = 0.18 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 4.07 (gradient I). 5-Amino-4-hvdroxy-2-isopropyl-7-r4-nnethoxy-3-(4-nnethoxybutyl)benzyll-8-nnethyl- nonanoic acid (tetrahvdropyran-4-yl)amide yellow oil; Rf = 0.20 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 4.19 (gradient I). 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1 ,2,2,6,6-pentamethylpiperidin-4-yl)amide dihydrochloride 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (2,2,6,6-tetramethylpiperidin-4-yl)amide colourless oil; Rf = 0.08 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.33 (gradient I). 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1-isopropylpiperidin-4-yl)amide yellowish oil; Rf = 0.39 (dichloromethane/methanol/conc. ammonia 25% 80:10:1); Rt = 3.21 (gradient I). 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1-isobutylpiperidin-4-yl)amide dihydrochloride 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid d-cvclopropylmethylpiperidin^-yDamide dihydrochloride 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1-propylpiperidin-4-yl)amide yellowish oil; Rf = 0.50 (dichloromethane/methanol/conc. ammonia 25% 80:10:1); Rt = 3.23 (gradient I). 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (1-ethylpiperidin-4-yl)amide yellowish oil; Rf = 0.47 (dichloromethane/methanol/conc. ammonia 25% 80:10:1);
Rt = 3.15 (gradient I). 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (tetrahydrofuran-2(S)-ylmethyl)amide yellowish oil; Rf = 0.36 (dichloromethane/methanol/conc. ammonia 25% 200:20:1);
Rt = 3.81 (gradient I). 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (furan-2-ylmethyl)amide yellowish oil; Rf = 0.19 (dichloromethane/methanol/conc. ammonia 25% 200:20:1);
Rt = 3.92 (gradient I). 44 5-Amino^-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (tetrahvdropyran-4-ylmethyl)amide colourless oil; Rf = 0.31 (dichloromethane/methanol/conc. ammonia 25% 200:20:1);
Rt = 3.61 (gradient I). 60 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (furan-3-ylmethyl)amide
63 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((cis)-1-oxaspiror2.5loct-6-yl)amide
The starting materials are prepared as follows:
a) (cis)-1-Oxaspiror2.5loct-6-ylamine and
(trans)-1-oxaspiror2.5loct-6-ylamine
A solution of 3.55 mmol of benzyl (1-oxaspiro[2.5]oct-6-yl)carbamate [142010-03-5] in 80 ml of methanol is hydrogenated in the presence of 0.13 mmol of Pd/C 10% (moist) at 00C for 1 hour. The reaction mixture is clarified by filtration and the catalyst is washed with ethanol. The filtrate is evaporated. The title compounds are identified from the residue by flash chromatography (SiO2 60F) on the basis of their Rf.
64 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((trans)-1-oxaspiror2.5loct-6-yl)amide
The starting material is prepared as described in Example 63.
65 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (tetrahvdropyran-2(R)-ylmethyl)amide
The starting materials are prepared as follows:
a) C-(Tetrahvdropyran-2(R)-yl)methylamine
A solution of 2.62 mmol of 2(R)-azidomethyltetrahydropyran in 150 ml of methanol is hydrogenated in the presence of 0.03 mmol of Pd/C 10% (moist) until conversion is complete. The reaction mixture is clarified by filtration and the catalyst is washed with ethanol. The filtrate is evaporated. The crude title compounds are identified from the residue on the basis of their Rf. b) 2(R)-Azidomethyltetrahvdropyran
A solution of 5 mmol of tetrahydropyran-2(R)-ylmethyl methanesulphonate and 55 mmol of sodium azide in 50 ml of dimethyl sulphoxide is stirred at room temperature for 20 hours. It is then diluted with water and tert-butyl methyl ether and washed with brine. The aqueous phase is extracted with tert-butyl methyl ether (2x). The combined organic phases are dried with sodium sulphate and evaporated. The crude title compound is identified from the residue on the basis of its Rf.
c) Tetrahvdropyran-2(R)-yl methyl methanesulphonate
50 mmol of triethylamine and 20 mmol of methanesulphonyl chloride are successively added to a solution of 10 mmol of (tetrahydropyran-2(R)-yl)methanol [70766-06-2] in 100 ml of dichloromethane at 0°C. The mixture is stirred at 0°C for 1 hour, diluted with dichloromethane and washed with 1 M HCI. The organic phase is dried with sodium sulphate and evaporated. The crude title compound is identified from the residue on the basis of its Rf.
66 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (tetrahvdropyran-2(S)-ylmethyl)amide
The starting material is prepared in analogy to Example 65 a-c from (tetrahydropyran-2(S)- yl)methanol [51450-44-3].
67 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (tetrahvdropyran-3(R)-yl)amide
The starting material is prepared in analogy to Example 65 a-c from tetrahydropyran-3(S)-ol [72886-97-6].
68 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (tetrahvdropyran-3(S)-yl)amide
The starting material is prepared in analogy to Example 65 a-c from tetrahydropyran-3(R)-ol [100937-76-6].
75 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (ri ,41dioxan-2(R,S)-ylmethyl)amide colourless wax; Rf = 0.26 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.56 (gradient I).
76 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid H ,41dioxepan-6-ylamide colourless wax; Rf = 0.18 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.56 (gradient I).
The starting material is prepared as follows:
a) H ,41Dioxepan-6-ylamine
A solution of 0.095 g of 6-azido[1 ,4]dioxepane in 2 ml of ethyl acetate is mixed with 0.053 g of 10% palladium/C (50%, moist with water), and the reaction mixture is hydrogenated with the aid of a balloon at room temperature for 45 minutes. The catalyst is filtered off through Hyflo. The filtrate is then employed directly in the amide coupling.
b) 6-AzidoH ,41dioxepane
A solution of 0.400 g of [1 ,4]dioxepan-6-yl toluene-4-sulphonate in 5 ml of N1N- dimethylformamide is mixed with 0.185 g of sodium azide. The reaction mixture is heated at 600C for 20 hours and then poured into water. The mixture is extracted with tert-butyl methyl ether, and the combined organic extracts are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained as a colourless oil from the residue by flash chromatography (SiO2 60F). Rf = 0.42 (EtOAc/heptane 1 :1).
c) H ,41Dioxepan-6-yl toluene-4-sulphonate
A solution of 0.470 g of [1 ,4]dioxepan-6-ol [28544-95-8] in 10 ml of dichloromethane is mixed with 0.836 ml of triethylamine and 0.050 g of N,N-dimethylaminopyridine. At room temperature, 0.824 g of toluene-4-sulphonyl chloride is added in portions and the reaction mixture is then stirred at room temperature for 3 hours. The reaction mixture is poured into saturated aqueous sodium bicarbonate solution. The mixture is extracted with tert-butyl methyl ether, and the combined extracts are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained as a colourless oil from the residue by flash chromatography (SiO2 60F). Rf = 0.29 (EtOAc/heptane 1 :1); Rt = 3.80 (gradient I). 77 5-Amino-4-hvdroxy-2-isopropyl-7-r4-nnethoxy-3-(3-nnethoxypropoxy)benzyll-8-nnethyl- nonanoic acid ((exo)-3-oxabicyclor3.1.01hex-6(R,S)-ylnnethyl)annicle yellow oil; Rf = 0.21 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.61 (gradient I).
The starting material is prepared as follows:
a) (exoVC-ri-O-Oxabicvcloβ.i .Olhex-e-vnimethylamine
65.3 g of lithium aluminium hydride (pellets) are added in portions to a stirred mixture of 70 g of (exo)-3-oxabicyclo[3.1.0]hexane-6-carboxamide and 1.1 I of tetrahydrofuran at 00C. The reaction mixture is stirred at room temperature for 19 hours. The resulting mixture is cooled to 00C and 100 ml of water, 100 ml of 1 M NaOH and 300 ml of water are successively added dropwise. The resulting suspension is clarified by filtration through Hyflo, and the filtrate is evaporated. The title compound is obtained as a colourless liquid from the residue by distillation, b.p. 65-75°C under 15 mbar.
b) (exo)-3-Oxabicvclor3.1.Olhexane-6-carboxamide
A mixture of 95.0 g of ethyl (exo)-3-oxabicyclo[3.1.0]hexane-6-carboxylate [CAS 81056-11-3] and 500 ml of aqueous 30% strength ammonia solution is stirred at room temperature for 3 days. The resulting emulsion is evaporated to dryness and the residue is dried in vacuo. The crude title compound is obtained as a brown solid.
78 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((exo,endo)-2-oxabicvclor3.1.01hex-6-ylmethyl)amide
The starting material is prepared in analogy to Example 77 a from (exo,endo)-2-oxa- bicyclo[3.1.0]hexane-6-carboxamide [89598-52-7].
79 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((exo,endo)-3-oxabicvclor3.1.01hex-6-yl)amide colourless oil; Rf = 0.21 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.50 (gradient I).
The starting material is prepared as follows:
a) (exoM3-Oxabicvclor3.1.0lhex-6-yl)amine A mixture of 7.0 g of tert-butyl (exo)-(3-oxabicyclo[3.1.0]hex-6-yl)carbamate and 52 ml of 4M HCI (in dioxane) is stirred at 00C for 1 hour and then at room temperature for 2 hours. The resulting suspension is cooled in an ice bath and, after addition of 200 ml of tert-butyl methyl ether, the solid ((exo)-(3-oxabicyclo[3.1.0]hex-6-yl)amine hydrochloride) is filtered off with suction.
The hydrochloride is added to a stirred mixture of 40 ml of 50% strength sodium hydroxide solution and 75 ml of tert-butyl methyl ether. The organic phase is separated off, dried with sodium hydroxide (solid), evaporated and distilled at 100 mbar/40°C. The title compound is obtained as a pale yellowish liquid.
b) tert-Butyl (exoM3-oxabicyclor3.1.Olhex-θ-vDcarbamate
A solution of 50.2 g of (exo)-3-oxabicyclo[3.1.0]hexane-6-carboxylic acid [CAS55780-88-6] and 450 ml of tert-butanol is warmed to 300C. Then, over the course of 30 minutes, 58.7 ml of triethylamine and 91.4 ml of diphenylphosphoryl azide are added dropwise in parallel. The reaction mixture is stirred at 70°C for 18 hours. The resulting mixture is evaporated, and the residue is mixed with 1 I of 1 M HCI and extracted with ethyl acetate (3x). The organic phases are washed with water (1x), 1 M sodium bicarbonate solution and brine (1x), dried with sodium sulphate and filtered, and the filtrate is evaporated. The title compound is obtained in the form of white crystals from the residue by flash chromatography and crystallization. Rf = 0.33 (EtOAc/heptane 1 :1); b.p. 86-87°C.
80 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((exo,endo)-2-oxabicvclor3.1.Olhex-θ-vDamide
The starting material is prepared in analogy to Example 79 a-b from (exo,endo)-2- oxabicyclo[3.1.0]hexane-6-carboxylic acid [99418-15-2].
81 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (6-oxaspiror2.5loct-1(R)-yl)amide colourless oil; Rf = 0.21 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.66 (gradient I). The starting materials are prepared as follows:
a) (RM6-Oxaspiror2.5loct-1-yl)amine
A solution of 0.528 g of (R)-6-oxaspiro[2.5]octane-1-carboxylic acid in 5 ml of tetrahydrofuran is mixed with 1.20 ml of triethylamine, and the solution is then cooled to 0°C. The solution is mixed with 0.657 ml of ethyl chloroformate, and the reaction mixture is stirred at 00C for 1 hour. A solution of 4.44 g of sodium azide in 5 ml of water is added and the reaction mixture is stirred at 00C for a further hour. The reaction mixture is diluted with water and extracted with tert-butyl methyl ether. The combined extracts are washed with brine, dried with sodium sulphate and evaporated. The residue is taken up in 5 ml of benzene, and the solution is heated to reflux for 2 hours and then evaporated. The residue is dissolved in 5 ml of tetrahydrofuran, and 5 ml of water and 0.347 g of lithium hydroxide are added. The reaction mixture is stirred at room temperature for 3 hours and then adjusted to pH 2 with 4M HCI. The tetrahydrofuran is distilled off, and the aqueous residue is adjusted to pH 12 with 2M NaOH. The aqueous phase is extracted with dichloromethane, and the combined organic extracts are dried over sodium sulphate and evaporated. The title compound is obtained as a yellow oil which is employed without further purification in the next stage. Rf = 0.26 (dichloromethane/methanol/conc. ammonia 25% 200:20:1).
b) (R)-6-Oxaspiror2.5loctane-1 -carboxylic acid
A solution of 3.700 g of (R)-4-benzyl-3-((R)-6-oxaspiro[2.5]octane-1-carbonyl)oxazolidin-2- one in 20 ml of tetrahydrofuran/water 3:1 is cooled to 0°C. 0.608 g of lithium hydroxide and 1.95 ml of hydrogen peroxide (30% in water) are added to the solution, which is stirred at room temperature for 6 hours. Saturated aqueous sodium thiosulphate solution is added to the reaction mixture, which is then extracted with tert-butyl methyl ether. The aqueous phase is adjusted to pH 2 with 4M HCI and extracted with dichloromethane. The combined extracts are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained as a colourless liquid and is employed without further purification for the next stage. Rf = 0.55 (dichloromethane/methanol/water/acetic acid 150:54:10:1); Rt = 2.10 (gradient I).
c) (R)-4-Benzyl-3-((R)-6-oxaspiror2.5loctane-1-carbonyl)oxazolidin-2-one and (R)-4-benzyl-3-((S)-6-oxaspiror2.5loctane-1-carbonyl)oxazolidin-2-one
A solution of 118.81 g of (R)-4-benzyloxazolidin-2-one [102029-44-7] in 90 ml of anhydrous tetrahydrofuran is cooled to -75°C under argon. A solution of n-butyllithium (1.6M in hexane) is added at -75° - -60°C over 2 hours. The reaction mixture is stirred at -75°C for 10 minutes and a solution of 110.37 g of 6-oxaspiro[2.5]octane-1-carbonyl chloride in 100 ml of tetra- hydrofuran is added dropwise at -75° - -60°C. The reaction mixture is then slowly warmed to 200C and saturated aqueous ammonium chloride solution is added. The mixture is extracted with tert-butyl methyl ether, and the combined extracts are washed with brine, dried with sodium sulphate and evaporated. The title compounds are obtained as white solids from the residue by column chromatography (SiO2 60F). Rf (diastereomer 1) = 0.25 (EtOAc/heptane 1 :2); Rt (diastereomer 1) = 4.20 (gradient I); Rf (diastereomer 2) = 0.21 (EtOAc/heptane 1 :2); Rt (diastereomer 2) = 4.27 (gradient I).
d) 6-Oxaspiror2.5loctane-1 -carbonyl chloride
60.0 ml of oxalyl chloride are added to a solution of 98.73 g of 6-oxaspiro[2.5]octane-1- carboxylic acid in 500 ml of dichloromethane at 0°C. One drop of N,N-dimethylformamide is added, and the reaction solution is stirred at room temperature for 1 hour. The reaction solution is then evaporated and the crude product is employed directly for the next stage.
e) 6-Oxaspiror2.5loctane-1 -carboxylic acid
A solution of 120.50 g of ethyl 6-oxaspiro[2.5]octane-1-carboxylate in 700 ml of ethanol/water 3.5:1 is mixed with 55.20 g of potassium hydroxide. The reaction mixture is heated at 600C for 4 hours, the ethanol is distilled off and the aqueous residue is diluted with water and extracted with tert-butyl methyl ether. The aqueous phase is adjusted to pH 2 with 4M hydrochloric acid and extracted with tert-butyl methyl ether. The combined organic extracts are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained as a yellowish oil and is employed without further purification for the next stage. Rt = 2.13 (gradient I).
f) Ethyl 6-oxaspiror2.5loctane-1 -carboxylate
51.93 g of sodium hydride (60% dispersion in oil) is taken up in 1100 ml of dry dimethyl sulphoxide under argon. 272 g of trimethylsulphoxonium iodide are added in portions over 20 minutes at room temperature, and the reaction mixture is then stirred at room temperature for 1.5 hours. 170.00 g of ethyl (tetrahydropyran-4-ylidene)acetate [130312-00-4] are added dropwise, and the reaction mixture is stirred at room temperature for 18 hours. The mixture is poured into ice and extracted with tert-butyl methyl ether. The combined organic extracts are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained as a colourless oil from the residue by vacuum distillation (68-70°C, 0.09 mbar). Rt = 3.49 (gradient I).
82 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (6-oxaspiror2.5loct-1(S)-yl)amide colourless oil; Rf = 0.21 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.69 (gradient I).
The starting materials are prepared as follows:
a) (S)-(6-Oxaspiror2.5loct-1-yl)amine
The title compound is prepared in analogy to Example 81 a-b from (R)-4-benzyl-3-((S)-6- oxaspiro[2.5]octane-1-carbonyl)oxazolidin-2-one (Example 81c).
83 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (6-oxaspiror2.5loct-1(R)-ylmethyl)amide yellowish oil; Rf = 0.28 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.74 (gradient I).
The starting material is prepared as follows:
a) C-F(S)-I -(6-Oxaspiror2.5loct-1 -yl)lmethylamine
10.60 g of lithium aluminium hydride are taken up in 160 ml of dry tetrahydrofuran under argon. The suspension is cooled to 00C, and a solution of 10.75 g of (S)-6-oxa- spiro[2.5]octane-1-carboxamide in 60 ml of tetrahydrofuran is added dropwise. The reaction mixture is stirred at 00C for 4 hours and then 7.80 ml of water, followed by 34 ml of 3M NaOH and 30 ml of water, are added. The solid is filtered off through Hyflo, and the filtrate is washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained as a yellowish oil and employed without further purification for the next stage.
b) (S)-6-Oxaspiror2.5loctane-1-carboxamide
A solution of 17.66 g of (S)-6-oxaspiro[2.5]octane-1-carboxylic acid (prepared in analogy to Example 81 b from (R)-4-benzyl-3-((S)-6-oxaspiro[2.5]octane-1-carbonyl)oxazolidin-2-one (Example 81c)) in 330 ml of ethyl acetate is mixed with 18.85 g of carbonyldiimidazole. The reaction solution is left to stand at room temperature for 6 hours and then 330 ml of 25% ammonium hydroxide solution are added. The reaction mixture is stirred at room temperature for 16 hours, the phases are separated, and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with water until neutral, dried with sodium sulphate and evaporated. The title compounds are obtained from the residue by flash chromatography (SiO2 60F) as a yellowish oil which may crystallize if sufficiently pure. Rf = 0.28 (dichloromethane/methanol/conc. ammonia 25% 200:20:1).
84 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (6-oxaspiror2.5loct-1(R)-ylmethyl)amide yellowish wax; Rf = 0.25 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.79 (gradient I).
The starting material is obtained in analogy to Example 83 from (R)-6-oxaspiro[2.5]octane-1- carboxylic acid (Example 81b).
85 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((Z)-2-oxabicyclor3.1.0lhex-1-ylmethyl)amide
The starting material is prepared as follows:
a) C-((Z)-2-Oxabicvclor3.1.Olhex-1 -vDmethylamine
The title compound is prepared in analogy to Example 65 a-c from ((Z)-2- oxabicyclo[3.1.0]hex-1-yl)methanol.
b) ((Z)-2-Oxabicvclor3.1.Olhex-1 -vDmethanol
2 mmol of a solution of borane-tetrahydrofuran complex (1 M in tetrahydrofuran) are added to a solution of 1.0 mmol of (Z)-2-oxabicyclo[3.1.0]hexane-1-carbaldehyde in 10 ml of tetrahydrofuran at room temperature. The reaction mixture is stirred at room temperature for 2 hours, mixed with 10 ml of methanol and concentrated. The title compound is identified on the basis of its Rf from the residue by means of flash chromatography (SiO2 60F).
c) (Z^-Oxabicvcloβ.i .Olhexane-i-carbaldehvde
A solution of 0.66 mmol of 1(Z)-propenyl-(Z)-2-oxabicyclo[3.1.0]hexane [164118-97-2] and 0.80 mmol of N-methylmorpholine N-oxide hydrate in 20 ml of tetrahydrofuran/water/tert- butanol 4:4:1 is stirred at room temperature for 30 minutes. A 4% strength solution of osmium tetroxide (4 mol% in water) is added, and the reaction mixture is stirred at room temperature for 16 hours and then quenched with 2M sodium thiosulphate solution and ethyl acetate. The mixture is stirred at room temperature for 3 hours, the phases are separated, and the organic phase is washed with brine and evaporated. The residue is dissolved in 20 ml of ethyl acetate, and 1.0 mmol of lead tetraacetate is added. The suspension is stirred at room temperature for 10 minutes and filtered through a little SiO2 6OF and evaporated. The title compound is identified on the basis of its Rf from the residue by flash chromatography (SiO2 60F).
87 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((exo,endo)-2-oxabicvclor4.1.01hept-7-ylmethyl)amide
The starting material is prepared as follows:
a) C-((exo,endo)-2-Oxabicvclor4.1.01hept-7-yl)methylamine
The title compound is prepared in analogy to Example 77 a-b from ethyl (exo,endo)-2- oxabicyclo[4.1.0]heptane-7-carboxylate [51197-04-7], [51144-35-5].
88 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (2-oxabicyclor4.1.01hept-7-yl)amide
The starting materials are prepared as follows:
a) (exo,endo)-2-Oxabicyclor4.1.Olhept-7-ylamine
The title compound is prepared in analogy to Example 79 a-b from (exo,endo)-2-oxa- bicyclo[4.1.0]heptane-7-carboxylic acid.
b) (exo,endo)-2-Oxabicyclor4.1.Olheptane-7-carboxylic acid
60 mmol of sodium periodate and 2 mmol of ruthenium(lll) chloride hydrate are added to a two-phase solution of 1.5 mmol of ((exo,endo)-2-oxabicyclo[4.1.0]hept-7-yl)methanol [51197-04-7], [51144-35-5] in 30 ml of water, 20 ml of tetrachloromethane and 20 ml of acetonitrile. The reaction mixture is stirred at room temperature for 3 hours and then quenched with isopropanol. The reaction mixture is filtered through Hyflo and evaporated. The title compound is identified on the basis of its Rf from the residue by flash chromatography (SiO2 60F).
89 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((7,9trans, 7exo)-7-methoxy-3-oxabicvclor3.3.1lnon-9-vl)amide The starting materials are prepared as follows:
a) (7,9trans, 7exo)-7-Methoxy-3-oxabicvclor3.3.1lnon-9-ylamine
A solution of 0.9 mmol of (7exo)-7-methoxy-3-oxabicyclo[3.3.1]nonan-9-one in 5 ml of ethanol is mixed with a solution of 1.8 mmol of hydroxylamine hydrochloride in 0.5 ml of water and heated to reflux overnight. The reaction mixture is concentrated and partitioned between saturated sodium carbonate solution and diethyl ether. The phases are separated and the aqueous phase is extracted with diethyl ether (2x). The combined organic phases are dried with sodium sulphate and evaporated. The residue is dissolved in 5 ml of ethanol, and 12.8 mmol of zinc dust and 0.8 ml of glacial acetic acid are each added alternately in small portions over the course of 2 hours. The internal temperature must not exceed 500C during the addition. The reaction mixture is stirred at room temperature for 12 hours and filtered through Hyflo, and the filter cake is washed with cold ethanol. The solution is evaporated and the residue is partitioned between 4M NaOH and diethyl ether. The phases are separated and the aqueous phase is extracted with diethyl ether (2x). The combined organic phases are dried with sodium sulphate and evaporated. The title compounds are identified on the basis of their Rf from the residue by flash chromatography (SiO2 60F).
b) (7exo)-7-Methoxy-3-oxabicvclor3.3.1lnonan-9-one
A solution of 1 mmol of (7exo)-7,9,9-trimethoxy-3-oxabicyclo[3.3.1]nonane in 10 ml of methanol is mixed with 10 ml of 2M HCI and heated to reflux for 3 hours. It is cooled to room temperature, and the reaction solution is concentrated. The residue is extracted with chloroform (3x). The combined organic phases are washed with sodium bicarbonate solution, dried with sodium sulphate and evaporated. The title compounds are identified on the basis of their Rf from the residue by flash chromatography (SiO2 60F).
c) (7exo)-7,9,9-Trimethoxy-3-oxabicvclor3.3.1lnonane
A solution of 1.3 mmol of (7exo)-9,9-dimethoxy-3-oxabicyclo[3.3.1]nonan-7-ol in 10 ml of dimethylformamide is mixed with 5.2 mmol of methyl iodide and cooled to 0°C. 1.9 mmol of sodium hydride (60% dispersion in oil) are added in portions, and the mixture is stirred at 00C for 1 hour. Saturated sodium bicarbonate solution is added, and the mixture is extracted with tert-butyl methyl ether (2x). The combined organic phases are washed with water and brine, dried with sodium sulphate and evaporated. The title compounds are identified on the basis of their Rf from the residue by flash chromatography (SiO2 60F). d) (7exo)-9,9-Dimethoxy-3-oxabicvclor3.3.1lnonan-7-ol
A solution of 4.5 mmol of (7endo)-9,9-dimethoxy-3-oxabicyclo[3.3.1]nonan-7-ol in 100 ml of tetrahydrofuran is mixed with 5.4 mmol of benzoic acid and 5.4 mmol of triphenylphosphine. Then 4.5 mmol of diisopropyl azodicarboxylate are added dropwise, and the mixture is stirred at room temperature for 5 hours. Saturated sodium bicarbonate solution is added, the phases are separated, and the aqueous phase is extracted with dichloromethane (2x). The combined organic phases are dried with sodium sulphate and evaporated. The residue is dissolved in 35 ml of methanol and, after addition of 17 mmol of potassium carbonate, stirred at room temperature for 5 hours. The reaction mixture is evaporated and the residue is taken up in dichloromethane. Saturated ammonium chloride solution is added, the phases are separated, and the aqueous phase is extracted with dichloromethane (2x). The combined organic phases are dried with sodium sulphate and evaporated. The title compounds are identified on the basis of their Rf from the residue by flash chromatography (SiO2 60F).
e) (7endo)-9,9-Dimethoxy-3-oxabicvclor3.3.1lnonan-7-ol
A solution of 1.89 mmol of 9,9-dimethoxy-3-oxabicyclo[3.3.1]nonan-7-one in 2 ml of tetrahydrofuran is added dropwise to a suspension of 3.68 mmol of lithium aluminium hydride in 4.5 ml of tetrahydrofuran at -200C. The reaction mixture is stirred at -200C for 40 hours. Then, 144 μl of water, 144 μl of 5M NaOH and 432 μl of water are cautiously added successively and the mixture is stirred at room temperature for 25 minutes. The reaction mixture is filtered through Hyflo and evaporated. The title compound is identified on the basis of its Rf from the residue by flash chromatography (SiO2 60F).
f) 9,9-Dimethoxy-3-oxabicvclor3.3.1lnonan-7-one
6 mmol of (7endo)-(9,9-dimethoxy-3-oxabicyclo[3.3.1]non-7-yl)phenylmethanone are added to a mixture of 6.7 mmol of potassium tert-butoxide in 25 ml of tert-butanol and 100 ml of hexamethyl phosphoric triamide under an oxygen atmosphere. The reaction mixture is stirred at room temperature for 30 minutes and poured into ice-water. It is extracted with benzene/tetrahydrofuran (3x). The combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compounds are identified by means of their Rf from the residue by flash chromatography (SiO2 60F). g) (7endoM9,9-Dimethoxy-3-oxabicvclor3.3.1lnon-7-yl)phenylmethanone A solution of 1 mmol of (7endo)-7-benzoyl-3-oxabicyclo[3.3.1]nonan-9-one in 20 ml of methanol is mixed with 1 ml of cone. H2SO4 and refluxed in a Dean-Stark apparatus for 3 hours. The reaction solution is cooled to room temperature and concentrated. The residue is extracted with chloroform (3x). The combined organic phases are washed with sodium bicarbonate solution, dried with sodium sulphate and evaporated. The title compounds are identified by means of their Rf from the residue by flash chromatography (SiO2 60F).
h) (7endo)-7-Benzoyl-3-oxabicvclor3.3.1lnonan-9-one
140 mg of tosyl chloride are added to a solution of 50 mmol of tetrahydropyran-4-one [29943-42-8] and 11 ml of pyrrolidine in 50 ml of benzene, and the reaction mixture is refluxed in a Dean-Stark apparatus for 3 hours. The reaction solution is cooled to room temperature and evaporated. The residue is dissolved in 200 ml of acetonitrile and 60 mmol of triethylamine and, after addition of a solution of 50 mmol of 2-benzoyl-1,3-dichloropropane [39192-57-9] in 100 ml of acetonitrile, stirred at room temperature for 2 hours. The reaction mixture is quenched with water, stirred for 1 hour and evaporated. The residue is mixed with water and extracted with chloroform (2x). The combined organic phases are washed with 2N HCI and 1 M sodium bicarbonate solution, dried with sodium sulphate and evaporated. The title compounds are identified by means of their Rf from the residue by flash chromatography (SiO2 60F).
90 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((7,9cis, 7endo)-7-methoxy-3-oxabicvclor3.3.1lnon-9-yl)amide
The starting material is prepared as follows:
a) (7,9cis, 7endo)-7-Methoxy-3-oxabicvclor3.3.1lnon-9-ylamine
The title compound is prepared in analogy to Example 91 a-c from (7endo)-9,9-dimethoxy-3- oxabicyclo[3.3.1]nonan-7-ol (Example 91 e).
96 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (tetrahvdrofuran-3S-ylmethvl)amide The starting material is prepared as follows:
a) C-(Tetrahydrofuran-3-yl)methylamine
The title compound is prepared in analogy to Example 65 a-c from (tetrahydrofuran-3S-yl)- methanol [124391-75-9].
97 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (tetrahydrofuran-3R-ylmethyl)amide
The starting material is prepared as follows:
a) C-(Tetrahydrofuran-3R-yl)methylamine
The title compound is prepared in analogy to Example 65 a-c from (tetrahydrofuran-3-yl)- methanol [124506-31-6].
98 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (tetrahydropyran-3R-ylmethyl)amide
The starting material is prepared as follows:
a) C-(Tetrahydropyran-3R-yl)methylamine
The title compound is prepared in analogy to Example 89 a from tetrahydropyran-3S- carbaldehyde [141822-85-7].
100 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (tetrahydrofuran-3R-yl)amide
101 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (tetrahydrofuran-3S-yl)amide
102 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (cis-5-methoxytetrahydropyran-3-yl)amide
The starting materials are prepared as follows:
a) cis-5-Methoxytetrahvdropyran-3-ylamine
The title compound is prepared in analogy to Example 79 a from cis-5-methoxytetrahydro- pyran-3-carboxylic acid. b) cis-5-Methoxytetrahvdropyran-3-carboxylic acid
A solution of 10.55 mmol of methyl cis-δ-nnethoxytetrahydropyran-S-carboxylate in 45 ml of methanol is mixed with 45 ml of 1 M LiOH and stirred at room temperature for one hour. The reaction mixture is evaporated and the residue is taken up in dichloromethane. The pH is adjusted to 2 with 2M HCI, the phases are separated, and the aqueous phase is extracted with dichloromethane (2x). The combined organic phases are dried with sodium sulphate and evaporated. The crude title compound is identified by means of its Rf from the residue.
c) Methyl cis-5-methoxytetrahvdropyran-3-carboxylate
15 ml of 50% NaOH, 367 mg of benzyltriethylammonium bromide and 0.95 ml of dimethyl sulphate are added to a solution of 1.5 g of methyl cis-5-hvdroxytetrahvdropyran-3- carboxylate in 30 ml of toluene. The two-phase mixture is stirred at room temperature for 18 hours. A further 1 ml of dimethyl sulphate is added. The mixture is stirred at room temperature for a further 6 hours and then diluted with water and ethyl acetate and stirred at room temperature for 20 minutes. The phases are separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained as a yellow oil from the residue by flash chromatography (SiO2 60F) and identified by means of the Rf.
d) Methyl cis-5-hydroxytetrahvdropyran-3-carboxylate
A solution of diazomethane in diethyl ether (approx. 0.4 M) is added in excess to a solution of 23 mmol of cis-S-hydroxytetrahydropyran-S-carboxylic acid in 300 ml of methanol at 00C. The mixture is stirred at 0°C for 2 hours and then quenched with magnesium sulphate, filtered and evaporated. The crude title compound is identified by means of the Rf.
e) cis-5-Hvdroxytetrahvdropyran-3-carboxylic acid
A solution of 25.5 mmol of cis-3,6-dioxabicyclo[3.2.1]octan-7-one in 500 ml of methanol is adjusted to pH 9 with 0.1 N NaOH. The solution is stirred at constant pH until conversion is complete and is adjusted to pH 6.5 with 0.1 N HCI before the methanol is evaporated off. The title compound is identified from the aqueous solution by means of the Rf by ion exchange chromatography (Amberlite XAD-2 resin). f) cis-3,6-Dioxabicyclor3.2.1loctan-7-one and methyl trans-5-hvdroxytetrahvdropyran-3-∞rboxylate
A solution of 39 mmol of methyl 5-oxotetrahydropyran-3-carboxylate [127956-19-8] in 500 ml of methanol is cooled to 0°C, and 50 mmol of sodium borohydride are added in portions. The solution is stirred at 00C for 3 hours and quenched with water. It is neutralized with acetic acid, and water and tert-butyl methyl ether are added. The phases are separated and the aqueous phase is extracted with tert-butyl methyl ether (2x). The combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compounds are identified by means of the Rf from the residue by flash chromatography (SiO2 60F).
103 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (trans-5-methoxytetrahvdropyran-3-yl)amide
The starting materials are prepared as follows:
a) trans-5-Methoxytetrahvdropyran-3-ylamine
The title compound is prepared in analogy to Example 79 a from trans-5-methoxytetrahydro- pyran-3-carboxylic acid.
b) trans-S-Methoxytetrahvdropyran^-carboxylic acid
The title compound is prepared in analogy to Example 102 b from methyl trans-5-methoxy- tetrahydropyran-3-carboxylate.
c) Methyl trans-5-methoxytetrahvdropyran-3-carboxylate
The title compound is prepared in analogy to Example 102 c from methyl trans-5- hydroxytetrahydropyran-3-carboxylate (Example 102 f).
104 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (cis-5-methoxytetrahvdropyran-3-ylmethvl)amide The starting material is prepared as follows:
a) cis-C-(5-Methoxytetrahvdropyran-3-yl)methylamine
The title compound is prepared in analogy to Example 65 a-c from cis-(5-methoxytetrahydro- pyran-3-yl)methanol.
b) cis-(5-Methoxytetrahydropyran-3-yl)methanol
The title compound is prepared in analogy to Example 81 c from methyl cis-5-methoxytetra- hydropyran-3-carboxylate (Example 102 c).
105 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (trans-5-methoxy-tetrahvdropyran-3-ylmethyl)amide
The starting material is prepared as follows:
a) trans-C-(5-Methoxytetrahvdropyran-3-yl)methylamine
The title compound is prepared in analogy to Example 104 a-b from methyl trans-5-methoxy- tetrahydropyran-3-carboxylate (Example 103 c).
106 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (cis-5-methoxyoxepan-3-yl)amide
The starting materials are prepared as follows:
a) cis-5-Methoxyoxepan-3-ylamine
The title compound is prepared in analogy to Example 102 a-b from methyl cis-5-methoxy- oxepane-3-carboxylate.
b) Methyl cis-5-methoxyoxepane-3-carboxylate
The title compound is prepared in analogy to Example 102 d-e from cis-3,7-dioxa- bicyclo[4.2.1]nonan-8-one.
c) cis-3,7-Dioxabicyclor4.2.1lnonan-8-one and methyl trans-5-hydroxyoxepane-3-carboxylate The title compounds are prepared in analogy to Example 102 f from methyl 5-oxooxepane-3- carboxylate [12756-13-2].
107 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (trans-5-methoxyoxepan-3-yl)amide
The starting materials are prepared as follows:
a) trans-5-Methoxyoxepan-3-ylamine
The title compound is prepared in analogy to Example 103 a-b from methyl trans-5-methoxy- oxepane-3-carboxylate.
b) Methyl trans-5-methoxyoxepane-3-carboxylate
The title compound is prepared in analogy to Example 103 c from methyl trans-5-hydroxy- oxepane-3-carboxylate (Example 106 c).
108 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (cis-5-methoxyoxepan-3-ylmethyl)amide
The starting material is prepared as follows:
a) cis-C-(5-Methoxyoxepan-3-yl)methylamine
The title compound is prepared in analogy to Example 104 a-b from methyl cis-5-methoxy- oxepane-3-carboxylate (Example 106 b).
109 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (trans-5-methoxyoxepan-3-ylmethyl)amide
The starting material is prepared as follows:
a) trans-C-(5-Methoxyoxepan-3-yl)methylamine
The title compound is prepared in analogy to Example 104 a-b from methyl trans-5-methoxy- oxepane-3-carboxylate (Example 107 b).
110 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (6R-methoxyoxepan-4-yl)amide The starting material is prepared as follows:
a) 6R-Methoxyoxepan-4-ylamine
2.8 mmol of sodium cyanoborohydride, 2.8 mmol of ammonium acetate and 530 mg of 4 A molecular sieves are added to a solution of 2.8 mmol of 6R-methoxyoxepan-4-one in 11 ml of methanol. The reaction mixture is stirred for 18 hours, and cone. HCI is added until the pH falls below 3 and a white precipitate becomes visible. It is concentrated and, after addition of water, extracted with dichloromethane (1x). The aqueous phase is adjusted to pH 12 with 6M NaOH and extracted with dichloromethane (3x). The combined organic phases are washed with water, dried with sodium sulphate and evaporated. The title compound is identified by means of the Rf from the residue by flash chromatography (SiO2 60F).
b) 6R-Methoxyoxepan-4-one
The title compound is prepared in analogy to Example 85 c from 3R-methoxy-5-methylene- oxepane.
c) 3R-Methoxy-5-methyleneoxepane
The title compound is prepared in analogy to Example 102 c from 3-hydroxy-5-methylene- oxepane [138907-09-2].
111 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (6-methoxy-oxepan-3-yl)amide
The starting material is prepared as follows:
a) 6-Methoxyoxepan-3-ylamine
The title compound is prepared in analogy to Example 110 a-c from 6-hydroxyoxepan-3-one
[120741-87-9].
112 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (4R-methoxytetrahvdrofuran-2R-ylmethyl)amide
The starting material is prepared as follows:
a) C-(4R-Methoxytetrahvdrofuran-2R-yl)methylamine The title compound is prepared in analogy to Example 65 a-c from (4R-methoxytetrahydro- furan-2R-yl)methanol.
b) (4R-Methoxytetrahvdrofuran-2R-yl)methanol
The title compound is prepared in analogy to Example 78 a from methyl 4R-Methoxy- tetrahydrofuran-2R-carboxylate.
c) Methyl 4R-methoxytetrahydrofuran-2R-carboxylate
The title compound is prepared in analogy to Example 102 c from methyl 4R-hydroxytetra- hydrofuran-2R-carboxylate.
d) Methyl 4R-hydroxytetrahvdrofuran-2R-carboxylate
The title compound is prepared in analogy to Example 89 d from methyl 4S-hydroxytetra- hydrofuran-2R-carboxylate [2208-93-7] .
113 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (4S-methoxytetrahvdrofuran-2R-ylmethyl)amide
The starting material is prepared as follows:
a) C-(4S-Methoxytetrahvdrofuran-2R-yl)methylamine
The title compound is prepared in analogy to Example 112 a-c from methyl 4S-hydroxytetra- hydrofuran-2R-carboxylate [2208-93-7] .
114 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (4R-methoxytetrahvdrofuran-2S-ylmethyl)amide
The starting material is prepared as follows:
a) C-(4R-Methoxytetrahvdrofuran-2S-yl)methylamine
The title compound is prepared in analogy to Example 112 a-c from methyl 4R-hydroxytetra- hydrofuran-2S-carboxylate [2209-10-1].
115 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (4S-methoxytetrahvdrofuran-2S-ylmethyl)amide The starting material is prepared as follows:
a) C-(4S-Methoxytetrahvdrofuran-2S-yl)methylamine
The title compound is prepared in analogy to Example 112 a-c from methyl 4S-hydroxytetra- hydrofuran-2S-carboxylate [2209-09-08] .
117 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((1S,2R,4SV7-oxabicvclor2.2.1lhept-2-vnamide
The starting materials are prepared as follows:
a) (1S,2R,4S)-7-Oxabicvclor2.2.1lhept-2-ylamine
The title compound is prepared in analogy to Example 79 a from (1S,2R,4S)-7- oxabicyclo[2.2.1]heptane-2-carboxylic acid.
b) (1S,2R,4S)-7-Oxabicvclor2.2.1lheptane-2-carboxylic acid
A solution of 1 mmol of (1S,2R,4S)-7-oxabicyclo[2.2.1]hept-5-ene-2-carboxylic acid [185840-15-7] in 30 ml of ethanol is hydrogenated in the presence of 0.15O g of Pd/C 10% at room temperature until conversion is complete. The reaction mixture is clarified by filtration and the filtrate is evaporated. The title compound is obtained from the residue by flash chromatography (SiO2 60F).
118 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((1 R,2S,4RV7-oxabicvclor2.2.1lhept-2-vnamide
The starting materials are prepared as follows:
a) (1 R,2S,4R)-7-Oxabicvclor2.2.1lhept-2-ylamine
The title compound is prepared in analogy to Example 117 a-b from (1R,2S,4R)-7-oxa- bicyclo[2.2.1]hept-5-ene-2-carboxylic acid.
b) (1 R,2S,4R)-7-Oxabicvclor2.2.1lhept-5-ene-2-carboxylic acid
A solution of 1 mmol of (1 R,2R)-2-(naphthalene-2-sulphonyl)cyclohexyl (exo)-(1ft,2S,4ft)-7- oxabicyclo[2.2.1]hept-5-ene-2-carboxylate in 5 ml of dimethylformamide is mixed with 2 mmol of potassium hydroxide and stirred at 600C for 17 hours. The reaction mixture is cooled to room temperature and, after addition of 1M citric acid solution, extracted with tert-butyl methyl ether (3x). The combined organic phases are washed with cold water and cold brine, dried with sodium sulphate and evaporated at room temperature. The title compound is identified by means of the Rf from the residue by flash chromatography (SiO2 60F).
119 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((1 R,2R,4RV7-oxabicvclor2.2.1lhept-2-vnamide
The starting material is prepared as follows:
a) (1 R,2R,4R)-7-Oxabicvclor2.2.1lhept-2-ylamine
The title compound is prepared in analogy to Example 117 a-b from (1 R,2R,4R)-7-oxa- bicyclo[2.2.1]hept-5-ene-2-carboxylic acid [90760-55-7].
120 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((1S,2S,4SV7-oxabicvclor2.2.1lhept-2-vnamide
The starting material is prepared as follows:
a) (1S,2S,4S)-7-Oxabicvclor2.2.1lhept-2-ylamine
The title compound is prepared in analogy to Example 117 a-b from (1S,2S,4S)-7-oxa- bicyclo[2.2.1]hept-5-ene-2-carboxylic acid [90760-56-8].
121 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid (2-oxabicvclor2.2.1lhept-6-yl)amide
The starting material is prepared as follows:
a) 2-Oxabicvclor2.2.1lhept-6-ylamine
The title compound is prepared in analogy to Example 89 a from 2-oxabicyclo[2.2.1]heptan-
6-one [34108-25-3].
122 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)benzyll-8-methyl- nonanoic acid ((exo)2,5-dioxabicvclor4.1.01hept-7-yl)amide The starting material is prepared as follows:
a) (exoM2,5-Dioxabicyclor4.1.01hept-7-yl)amine
The title compound is prepared in analogy to Example 79 a-b from (exo)-2,5-dioxa- bicyclo[4.1.0]heptane-7-carboxylic acid [60170-70-9].
123 5-Amino-4-hvdroxy-2-isopropyl-7-r(S)-(3S,4S)-4-methoxy-3-(3-methoxypropoxy)- benzyll-8-methylnonanoic acid r(exo)-1-(2,5-dioxabicyclor4.1.Olhept-7- vDmethyllamide
The starting material is prepared as follows:
a) (exoM2,5-Dioxabicyclor4.1.01hept-7-ylmethyl)amine
The title compound is prepared in analogy to Example 77 a-b from ethyl (exo)-2,5-dioxa- bicyclo[4.1.0]heptane-7-carboxylate [60170-67-4].
124 (2S,4S,5S,7S)-5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3- methoxypropoxy)benzyll-8-methylnonanoic acid KcJs)-I -O-oxabicycloβ.1.Olhex-2- vDmethyllamide
The starting material is prepared as follows:
a) C-KcisM -P-Oxabicvcloβ.1.Olhex-2-vnimethylamine
The title compound is prepared in analogy to Example 77 a-b and Example 88 from methyl (cis)-3-oxabicyclo[3.1.0]hexane-2-carboxylate.
b) Methyl (cis)-3-oxabicyclor3.1.Olhexane-2-carboxylate
The title compound is prepared in analogy to Example 102 d from (cis)-3-oxa- bicyclo[3.1.0]hexane-2-carboxylic acid.
c) (cis)-3-Oxabicyclor3.1.Olhexane-2-carboxylic acid
The title compound is prepared in analogy to Example 88 from (cis)-3-oxa- bicyclo[3.1.0]hexane-2-methanol [85194-16-7].
127 (2S,4S,5S,7S)-5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)- benzyll-8-methylnonanoic acid r2-methyl-2-(tetrahvdropyran-4-yl)propyllamide The starting material is prepared as follows:
a) 2-Methyl-2-(tetrahvdropyran-4-yl)propylamine
The title compound is prepared in analogy to Example 77 a-b from ethyl 2-methyl-2-
(tetrahydropyran-4-yl)propionate [865156-84-9].
128 (2S,4S,5S,7S)-5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(3-methoxypropoxy)- benzyll-8-methylnonanoic acid r2,2-difluoro-2-(tetrahvdropyran-4-yl)ethyllamide
The starting material is prepared as follows:
a) 2,2-Difluoro-2-(tetrahvdropyran-4-yl)ethylamine
The title compound is prepared in analogy to Example 77 a-b from methyl difluoro- (tetra hyd ro pyra n-4-yl )acetate .
b) Methyl difluoro(tetrahvdropyran-4-yl)acetate
The title compound is prepared in analogy to Example 102 d from difluoro(tetrahydropyran-4- yl)acetic acid.
c) Difluoroftetrahydropyran^-vDacetic acid
A solution of 0.774 mmol of 2-[1 ,1-dichloro-2,2-difluoro-2-(tetrahydropyran-4-yl)ethyl- sulphanyljpyridine in 4 ml of tetrahydrofuran is mixed with 3.096 mmol of silver nitrate solution (in 4 ml of water). The cloudy mixture is heated to reflux for 3 hours. The reaction mixture is cooled to room temperature and filtered through Hyflow. The filtrate is adjusted to pH 9-10 with 50% strength sodium bicarbonate solution and washed with diethyl ether. The aqueous phase is subsequently adjusted to pH 1 with 50% strength H2SO4 and extracted with dichloromethane. The combined organic phases are dried with sodium sulphate and evaporated. The title compound is obtained as a yellow solid from the residue.
d) 2-H , 1 -Dichloro^^-difluoro^-ftetrahvdropyran^-vDethylsulphanyllpyridine 2.422 mmol of N.N'-dicyclohexylcarbodiimide are added to a solution of 2.422 mmol of tetrahydropyran-4-carboxylic acid [5337-03-1] and 2.422 mmol of hydroxythiopyrimidone [1121-31-9] in 5 ml of dichloromethane at room temperature with exclusion of light. The reaction mixture is stirred at room temperature for 3 hours. It is filtered through Hyflow, and the filtrate is evaporated with exclusion of light. The yellow residue is dissolved in 4 ml of acetonitrile, the solution is cooled to 0°C, and 24.22 mmol of 1 ,1-dichloro-2,2-difluoro- ethylene [79-35-6] are added. The reaction mixture is stirred under the influence of light (300 W sunlamp) at -10°C for 2.5 hours. It is evaporated. The title compound is obtained as a pale yellow oil from the residue by flash chromatography (SiO2 60F). Rf = 0.26 (EtOAc/heptanei :1); Rt = 4.25 (gradient I).
Example 30:
5-Amino-4-hvdroxy-2-isopropyl-7-r3-(3-methoxypropoxy)-4-methylbenzyll-8-methylnonanoic acid pyrrolidin-3(S)-ylamide
0.35 g of tert-butyl 3(S)-{5-tert-butoxycarbonylamino-4-hydroxy-2-isopropyl-7-[3-(3-methoxy- propoxy)-4-methylbenzyl]-8-methylnonanoylamino}pyrrolidine-1-carboxylate is reacted in analogy to Method K. The title compound is obtained as a white foam. Rf = 0.13 (dichloromethane/methanol/conc. ammonia 25% 40:10:1); Rt = 3.56 (gradient I).
The starting materials are prepared as follows:
a) tert-Butyl 3(SM5-tert-butoxycarbonylamino-4-hvdroxy-2-isopropyl-7-r3-(3-methoxy- propoxy)-4-methylbenzyll-8-methylnonanoylamino}pyrrolidine-1-carboxylate
0.400 g of tert-butyl {1-(4-isopropyl-5-oxotetrahydrofuran-2-yl)-3-[3-(3-methoxypropoxy)-4- methylbenzyl]-4-methylpentyl}carbamate is reacted with tert-butyl (S)-3-aminopyrrolidine-1- carboxylate [147081-44-5] in analogy to Method B. The title compound is obtained as a white solid. Rf = 0.12 (EtOAc/heptane 1 :1); Rt = 5.66 (gradient I).
b) tert-Butyl (1-(4-isopropyl-5-oxotetrahvdrofuran-2-yl)-3-r3-(3-methoxypropoxy)-4-methyl- benzyll-4-methylpentyl}carbamate
5.8 g of 5-{1-amino-3-[3-(3-methoxypropoxy)-4-methylbenzyl]-4-methylpentyl}-3-isopropyl- dihydrofuran-2-one are reacted in analogy to Method J. The title compound is obtained as a beige oil. Rf = 0.31 (EtOAc/heptane 1 :3); Rt = 6.16 (gradient I).
c) 5-(1-Amino-3-r3-(3-methoxypropoxy)-4-methylbenzyll-4-methylpentyl}-3-isopropyl- dihvdrofuran-2-one
8.0 g of 2-[2-azido-2-(4-isopropyl-5-oxotetrahydrofuran-2-yl)ethyl]-1-[3-(3-methoxypropoxy)- 4-methylphenyl]-3-methylbutyl methoxyacetate are reacted in analogy to Method I. The title compound is obtained as a yellow oil. Rf = 0.05 (EtOAc/heptane 1 :1); Rt = 4.55 (gradient I). d) 2-r2-Azido-2-(4-isopropyl-5-oxotetrahvdrofuran-2-yl)ethyll-1-r3-(3-nnethoxypropoxy)-4- methylphenyll-3-methylbutyl methoxyacetate
8.0 g of 5-(1-azido-3-{hydroxy-[3-(3-methoxypropoxy)-4-methylphenyl]nnethyl}-4-nnethyl- pentyl)-3-isopropyldihydrofuran-2-one are reacted in analogy to Method H. The title compound is obtained as a yellow oil. Rf = 0.17 (EtOAc/heptane 1 :2); Rt = 5.70 (gradient I).
e) 5-(1-Azido-3-(hvdroxy-r3-(3-methoxypropoxy)-4-methylphenyllmethyl}-4-methylpentyl)-3- isopropyldihvdrofuran-2-one
6.0 g of 4-bromo-2-(3-methoxypropoxy)-1-methylbenzene are reacted in analogy to Method G. The title compound is obtained as a beige oil. Rf = 0.38 (EtOAc/heptane 1 :1); Rt = 5.29 und 5.57 (gradient I).
f) 4-Bromo-2-(3-methoxypropoxy)-1 -methyl benzene
6.0 g of 4-bromo-1-methylphenol [2362-12-1] are reacted in analogy to Method L. The title compound is obtained as an orange oil. Rf = 0.38 (EtOAc/heptane 1 :10); Rt = 5.37 (gradient I).
The following compounds are prepared in an analogous manner to the process described in Example 30:
31 5-Amino-4-hvdroxy-2-isopropyl-7-r3-(3-methoxypropoxy)-4-methylbenzyll-8-methyl- nonanoic acid pyrrolidin-3(R)-ylamide
White foam; Rf = 0.11 (dichloromethane/methanol/conc. ammonia 25% 40:10:1);
Rt = 3.63 (gradient I). 40 5-Amino-4-hvdroxy-2-isopropyl-7-r3-(3-methoxypropoxy)-4-methylbenzyll-8-methyl- nonanoic acid (tetrahydrofuran-2(S)-ylmethyl)amide
Yellowish oil; Rf = 0.52 (dichloromethane/methanol/conc. ammonia 25% 200:20:1);
Rt = 4.27 (gradient I). 34 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(4-methoxybutyl)benzyll-8-methyl- nonanoic acid pyrrolidin-3(S)-ylamide
Colourless resin; Rf = 0.06 (dichloromethane/methanol/conc. ammonia 25% 30:20:1);
Rt = 3.53 (gradient I). The starting materials are prepared as follows:
a) 4-Bromo-1-methoxy-2-(4-methoxybutyl)benzene
A solution of 0.435 mg of 4-bromo-1-methoxy-2-(4-methoxybut-1-enyl)benzene in 23 ml of ethyl acetate at 0°C is mixed with 92 μl of glacial acetic acid and hydrogenated in the presence of 600 mg of Pd/C 10% (moist) at 00C for 1.2 hours. The reaction mixture is clarified by filtration and the catalyst is washed with ethanol. The filtrate is evaporated. The residue is treated with 1 M sodium bicarbonate solution and extracted with tert-butyl methyl ether (3x) - the combined organic phases are dried with sodium sulphate and evaporated. The title compound is obtained as a yellow oil from the residue by flash chromatography (SiO2 60F). Rf = 0.38 (EtOAc/heptane 1 :4); Rt = 5.35 (gradient I).
b) 4-Bromo-1 -methoxy-2-(4-methoxybut-1 -envDbenzene
A solution of 1.6 g of (3-methoxypropyl)triphenylphosphonium iodide [133622-76-1] in 7.5 ml of tetrahydrofuran at 00C is mixed with 3.5 ml of sodium bis(trimethylsilyl)amide solution (1 M in tetrahydrofuran) and stirred at 0°C for 30 minutes. Then 500 mg of 5-bromo-2-methoxy- benzaldehyde are added, and the reaction mixture is warmed to room temperature. After 1 hour, it is diluted with 1 M sodium bicarbonate solution and tert-butyl methyl ether. The phases are separated, and the organic phase is washed with 1 M sodium bicarbonate solution, dried with sodium sulphate and evaporated. The title compound is obtained as an orange oil from the residue by flash chromatography (SiO2 60F). Rf = 0.36 (EtOAc/heptane 1 :4); Rt = 5.10 (gradient I).
35 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(4-methoxybutyl)benzyll-8-methyl- nonanoic acid pyrrolidin-3(R)-ylamide
Yellow resin; Rf = 0.06 (dichloromethane/methanol/conc. ammonia 25% 30:20:1);
Rt = 3.62 (gradient I). 43 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(4-methoxybutyl)benzyll-8-methyl- nonanoic acid (tetrahvdrofuran-2(S)-ylmethyl)amide
Yellow oil; Rf = 0.27 (dichloromethane/methanol/conc. ammonia 25% 200:20:1);
Rt = 4.44 (gradient I). 41 5-Amino-7-r3-ethyl-4-(3-methoxypropoxy)benzylH-hvdroxy-2-isopropyl-8-methyl- nonanoic acid (tetrahvdrofuran-2(S)-ylmethyl)amide
Yellowish oil; Rf = 0.43 (dichloromethane/methanol/conc. ammonia 25% 200:20:1);
Rt = 4.41 (gradient I). The starting material is prepared as follows:
a) 4-Bromo-2-ethyl-1-(3-methoxypropoxy)benzene
17.6 g of 4-bromo-2-ethylphenol [18980-21-7] are reacted in analogy to Method L. The title compound is obtained as a colourless oil. Rf = 0.38 (EtOAc/heptane 1 :4); Rt = 5.64 (gradient I).
42 5-Amino-7-r3-ethyl-4-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8-methyl- nonanoic acid (tetrahydropyran-4-yl)amide
Yellowish oil; Rf = 0.38 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 4.20 (gradient I).
51 5-Amino-7-r4-ethyl-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8-methyl- nonanoic acid (tetrahydropyran-4-yl)amide
Yellowish oil; Rf = 0.45 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 4.34 (gradient I).
The starting material is prepared as follows:
a) 5-Bromo-2-ethyl-1-(3-methoxypropoxy)benzene
19.1 g of 5-bromo-2-ethylphenol [56152-25-1] are reacted in analogy to Method L. The title compound is obtained as a colourless liquid. Rf = 0.55 (EtOAc/heptane 1 :4); Rt = 5.66 (gradient I).
69 5-Amino-7-r4-ethyl-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8-methyl- nonanoic acid (tetrahydrofuran-2(S)-ylmethyl)amide
52 5-Amino-7-r4-cvclopropyl-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8- methylnonanoic acid (tetrahydropyran-4-yl)amide
Yellow oil; Rf = 0.21 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 4.29 (gradient I).
The starting materials are prepared as follows:
a) 4-Bromo-1-cvclopropyl-2-(3-methoxypropoxy)benzene
A solution of 164 ml of diethyl zinc solution (1M in hexane) in 224 ml of dichloromethane at
0°C is mixed with a solution of 12.5 ml of trifluoroacetic acid in 111 ml of dichloromethane and stirred at 0°C for 20 minutes. Then a solution of 13.2 ml of diiodomethane in 111 ml of dichloromethane is added, and the mixture is stirred at 00C for 20 minutes. A solution of 22.3 g of 4-bromo-2-(3-methoxypropoxy)-1-vinylbenzene in 111 ml of dichloromethane is added, and the mixture is warmed to room temperature and stirred for 30 minutes. The reaction mixture is quenched with saturated ammonium chloride solution, and the phases are separated. The aqueous phase is extracted with dichloromethane (2x) - the combined organic phases are washed with saturated sodium bicarbonate solution and brine, dried with sodium sulphate and evaporated. The title compound is obtained as a yellow oil from the residue by flash chromatography (SiO2 60F). Rf = 0.40 (EtOAc/heptane 1 :6); Rt = 5.50 (gradient I).
b) 4-Bromo-2-(3-methoxypropoxy)-1 -vinyl benzene
A solution of 27.7 g of 1-[4-bromo-2-(3-methoxypropoxy)phenyl]ethanol in 1 I of dimethyl sulphoxide is mixed with 13.18 g of potassium hydrogensulphate. The reaction mixture is stirred at 180°C (preheated oil bath) for 2.5 hours and cooled to room temperature. The reaction mixture is partitioned between tert-butyl methyl ether and water. The aqueous phase is extracted with tert-butyl methyl ether (2x) - the combined organic phases are dried with sodium sulphate and evaporated. The title compound is obtained as a yellow oil from the residue by flash chromatography (SiO2 60F). Rf = 0.25 (EtOAc/heptane 1 :6); Rt = 5.38 (gradient I).
c) 1-r4-Bromo-2-(3-methoxypropoxy)phenyllethanol
200 mg of sodium borohydride are added in portions to a solution of 1.12 g of 1-[4-bromo-2- (3-methoxypropoxy)phenyl]ethanone in 50 ml of ethanol at 0°C. The reaction mixture is warmed to room temperature and stirred at room temperature overnight. The reaction mixture is poured into ice-water and stirred for 15 minutes. The solution is adjusted to pH 5 with glacial acetic acid. The resulting solution is extracted with tert-butyl methyl ether (3x) - the combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained as a colourless oil from the residue by flash chromatography (SiO2 60F). Rf = 0.45 (EtOAc/heptane 1 :1); Rt = 4.16 (gradient I).
d) 1-r4-Bromo-2-(3-methoxypropoxy)phenyllethanone
50 g of 1-(4-bromo-2-hydroxyphenyl)ethanone [30186-18-6] are reacted in analogy to Method L. The title compound is obtained as a yellow oil. Rf = 0.30 (EtOAc/heptane 1 :2); Rt = 4.59 (gradient I). 70 5-Amino-7-r4-cvclopropyl-3-(3-nnethoxypropoxy)benzylH-hvclroxy-2-isopropyl-8- methylnonanoic acid (tetrahvdrofuran-2(S)-ylmethyl)amide
56 5-Amino-4-hvdroxy-2-isopropyl-7-r3-(3-nnethoxypropoxy)-4-trifluoronnethoxybenzyll-8- methylnonanoic acid (tetrahvdropyran-4-yl)amide
The starting materials are prepared as follows:
a) 4-Bromo-2-(3-methoxypropoxy)-1-trifluoromethoxybenzene
20 mmol of 1-(4-bromo-2-hydroxyphenyl)ethanone [30186-18-6] are reacted in analogy to Method L. The title compound is identified by means of its Rf.
b) 5-Bromo-2-trifluoromethoxyphenol
A solution of 210 mmol of sodium nitrite in 120 ml of water is added dropwise to a suspension of 200 mmol of 5-bromo-2-trifluoromethoxyaniline in 500 ml of ethanol and 50 ml of cone. HCI at 00C. The reaction mixture is stirred at 5°C for 1.5 hours. The reaction mixture is slowly added dropwise to a solution of 135 ml of cone, sulphuric acid in 2.8 I of water and stirred under reflux overnight. The reaction mixture is extracted with diethyl ether (3x) - the combined organic phases are washed with water and 1 M sodium bicarbonate solution and then extracted with 2N NaOH (2x). The combined aqueous phases are acidified with cone. HCI and extracted with diethyl ether (3x). The combined organic phases are washed with water, dried with sodium sulphate and evaporated. The crude title compound is obtained from the residue.
57 5-Amino-4-hvdroxy-2-isopropyl-7-r3-(3-methoxypropoxy)-4-trifluoromethylbenzyll-8- methylnonanoic acid (tetrahvdropyran-4-yl)amide
The starting material is prepared as follows:
a) 4-Bromo-2-(3-methoxypropoxy)-1-trifluoromethyl benzene
10.4 mmol of sodium hydride (60% dispersion in oil) are added in portions to a solution of 8.7 mmol of 3-methoxypropanol [1589-49-7] in 12 ml of dimethyl sulphoxide. The reaction mixture is stirred at room temperature for 30 minutes, and 1.3 g of sodium benzoate are added. The mixture is stirred at room temperature for 30 minutes, and 10.6 mmol of 4-bromo- 2-fluoro-1-trifluoromethylbenzene [1428808-15-9] are added in such a way that the internal temperature does not exceed 200C. After the addition is complete, the mixture is heated at 65°C for 15 hours. It is then cooled to room temperature. The reaction mixture is quenched with water/brine 1 :1 and extracted with dichloromethane (2x) - the combined organic phases are washed with brine, dried with sodium sulphate and evaporated. The title compound is identified by means of its Rf from the residue by flash chromatography (SiO2 60F).
72 5-Amino-4-hvdroxy-2-isopropyl-7-r3-(3-methoxypropoxy)-4-trifluoromethylbenzyll-8- methylnonanoic acid (tetrahvdrofuran-2(S)-ylmethyl)amide
91 5-Amino-7-r4-fluoro-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8-methyl- nonanoic acid (tetrahvdrofuran-2(S)-ylmethyl)amide
The starting material is prepared as follows:
a) 4-Bromo-1-fluoro-2-(3-methoxypropoxy)benzene
30.22 g of 5-bromo-2-fluorophenol [112204-58-7] are reacted in analogy to Method L. The title compound is identified by means of its Rf.
92 5-Amino-7-r4-fluoro-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8-methyl- nonanoic acid (tetrahvdropyran-4-yl)amide
93 5-Amino-7-r4-fluoro-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8-methyl- nonanoic acid (tetrahvdropyran-4-ylmethyl)amide
94 5-Amino-7-r4-fluoro-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8-methyl- nonanoic acid ((exo,endo)-3-oxabicvclor3.1.01hex-6-ylmethyl)amide
The starting material is prepared as described in Example 78.
95 5-Amino-7-r4-fluoro-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8-methyl- nonanoic acid ((Z)-2-oxabicvclor3.1.Olhex-i-ylmethvDamide
The starting material is prepared as described in Example 85.
Example 32:
5-Amino-4-hvdroxy-2-isopropyl-7-r3-(3-methoxypropoxy)-4-methylbenzyll-8-methylnonanoic acid piperidin-4-ylamide
220 mg of tert-butyl [2-hydroxy-1-{2-[3-(3-methoxypropoxy)-4-methylbenzyl]-3-methylbutyl}- 5-methyl-4-(piperidin-4-ylcarbamoyl)hexyl]carbamate are reacted in analogy to Method K. The title compound is obtained as a white foam. Rf = 0.13 (dichloromethane/methanol/conc. ammonia 25% 40:10:1); Rt = 3.55 (gradient I).
The starting materials are prepared as follows:
a) tert-Butyl r2-hvdroxy-1-(2-r3-(3-methoxypropoxyH-methylbenzyll-3-methylbutyl}-5- methyl-4-(piperidin-4-ylcarbamoyl)hexyllcarbamate
A solution of 358 mg of benzyl 4-{5-tert-butoxycarbonylamino-4-hydroxy-2-isopropyl-7-[3-(3- methoxypropoxy)-4-methylbenzyl]-8-methylnonanoylamino}piperidin-1-carboxylate in 15 ml of ethanol and 0.03 ml of ethanolamine is hydrogenated in the presence of 152 mg of Pd/C 10% (moist) at 0°C for 1 hour. The reaction mixture is clarified by filtration and the catalyst is washed with ethanol. The filtrate is evaporated. The title compound is obtained as a white foam from the residue by flash chromatography (SiO2 60F). Rf = 0.1 (dichloromethane/ methanol/conc. ammonia 25% 200:20:1); Rt = 4.74 (gradient I).
b) Benzyl 4-(5-tert-butoxycarbonylamino-4-hvdroxy-2-isopropyl-7-r3-(3-methoxypropoxy)-4- methylbenzyll-8-methylnonanoylaminolpiperidine-i-carboxylate
0.400 g of tert-butyl {1-(4-isopropyl-5-oxotetrahydrofuran-2-yl)-3-[3-(3-methoxypropoxy)-4- methylbenzyl]-4-methylpentyl}carbamate (Example 30 b) is reacted with benzyl 4-amino- piperidine-1-carboxylate [120278-07-1] in analogy to Method B. The title compound is obtained as a white foam. Rf = 0.18 (EtOAc/heptane 1 :1); Rt = 5.72 (gradient I).
The following compound is prepared in an analogous manner to the process described in Example 32:
33 5-Amino-4-hvdroxy-2-isopropyl-7-r4-methoxy-3-(4-methoxybutyl)benzyll-8-methyl- nonanoic acid piperidin-4-ylamide
Yellowish foam; Rf = 0.06 (dichloromethane/methanol/conc. ammonia 25% 50:10:1); Rt = 3.55 (gradient I).
Example 45:
5-Amino-7-r4-(1 , 1 -difluoroethyl)-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8- methylnonanoic acid (tetrahvdropyran-4-yl)amide
3.6 ml of HCI (1M in dioxane) are added to 360 mg of tert-butyl [1-{2-[4-(1,1-difluoroethyl)-3-
(3-methoxypropoxy)benzyl]-3-methylbutyl}-2-hydroxy-5-methyl-4-(tetrahydropyran-4- ylcarbamoyl)hexyl]carbamate at 0°C. The reaction mixture is poured into ice/1 M sodium bicarbonate solution and extracted with tert-butyl methyl ether (3x) - the combined organic phases are dried with sodium sulphate and evaporated. The title compound is obtained as a white foam from the residue by flash chromatography (SiO2 60F). Rf = 0.17 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 4.14 (gradient I).
The starting materials are prepared as follows:
a) tert-Butyl H -(2-F4-(1 , 1 -difluoroethvn-3-(3-methoxypropoxy)benzyll-3-methylbutyl}-2- hvdroxy-5-methyl-4-(tetrahvdropyran-4-ylcarbamoyl)hexyllcarbamate
The title compound is obtained as a white foam in analogy to Example 30, sequence a-e, from 4-bromo-1-(1,1-difluoroethyl)-2-(3-methoxypropoxy)benzene. Rf = 0.19 (EtOAc/heptane 2:1); Rt = 5.33 (gradient I).
b) 4-Bromo-1 -(1 ,1 -difluoroethyl)-2-(3-methoxypropoxy)benzene
A solution of 15.7 g of 1-[4-bromo-2-(3-methoxypropoxy)phenyl]ethanone (Example 52 d) in 2.78 ml of Deoxofluor(R) in a Teflon vessel is stirred at 85°C for 2 days. The reaction mixture is poured into cold 1 M sodium bicarbonate solution and extracted with dichloromethane (2x) - the combined organic phases are dried with sodium sulphate and evaporated. The title compound is obtained as a yellow liquid from the residue by flash chromatography (SiO2 60F). Rf = 0.67 (EtOAc/heptane 1 :1); Rt = 5.02 (gradient I).
The following compound is prepared in an analogous manner to the process described in Example 45:
47 5-Amino-7-r4-(1 , 1 -difluoroethyl)-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl- 8-methylnonanoic acid (tetrahvdrofuran-2(S)-ylmethyl)amide Yellowish oil; Rf = 0.22 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 4.32 (gradient I).
Example 46:
7-r4-Acetyl-3-(3-methoxypropoxy)benzyll-5-amino-4-hvdroxy-2-isopropyl-8-methylnonanoic acid (tetrahvdropyran-4-yl)amide
0.42 g of tert-butyl [1-{2-[4-(1,1-difluoroethyl)-3-(3-methoxypropoxy)benzyl]-3-methylbutyl}- 2-hydroxy-5-methyl-4-(tetrahydropyran-4-ylcarbamoyl)hexyl]carbamate (Example 45 a) is reacted in analogy to Method K. The title compound is obtained as a yellow oil. Rf = 0.16 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.59 (gradient I).
The following compound is prepared in an analogous manner to the process described in Example 46:
48 7-r4-Acetyl-3-(3-methoxypropoxy)benzyll-5-amino-4-hvdroxy-2-isopropyl-8-methyl- nonanoic acid (tetrahydrofuran-2(S)-ylmethyl)amide
Yellowish oil; Rf = 0.25 (dichloromethane/methanol/conc. ammonia 25% 200:20:1); Rt = 3.76 (gradient I).
Example 53:
5-Amino-7-r4-chloro-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8-methylnonanoic acid (tetrahydropyran-4-yl)amide
30 mg of tert-butyl [1-{2-[4-chloro-3-(3-methoxypropoxy)benzyl]-3-methylbutyl}-2-hydroxy-5- methyl-4-(tetrahydropyran-4-ylcarbamoyl)hexyl]carbamate are reacted in analogy to Method K. The title compound is obtained as a colourless glass. Rf = 0.34 (dichloromethane/ methanol/conc. ammonia 25% 200:20:1); Rt = 4.02 (gradient I).
The starting materials are prepared as follows:
a) tert-Butyl ri-(2-r4-chloro-3-(3-methoxypropoxy)benzyll-3-methylbutyl}-2-hvdroxy-5- methyl-4-(tetrahvdropyran-4-ylcarbamoyl)hexyllcarbamate
63 mg of tert-butyl [3-[4-chloro-3-(3-methoxypropoxy)benzyl]-1-(4-isopropyl-5-oxotetrahydro- furan-2-yl)-4-methylpentyl]carbamate are reacted in analogy to Method B. The title compound is obtained as a colourless oil. Rf = 0.15 (EtOAc/heptane 2:1); Rt = 5.16 (gradient I).
b) tert-Butyl r3-r4-chloro-3-(3-methoxypropoxy)benzyll-1-(4-isopropyl-5-oxotetrahvdrofuran- 2-yl )-4-methyl pe ntyllcarba mate
Tributyltin hydride (0.36 ml) is added to a degassed solution of 0.676 g of 0-{2-[2-tert- butoxycarbonylamine-2-isopropyl-5-oxotetrahydrofuran-2-yl)ethyl-1-[4-chloro-3-(3-methoxy- propoxy)phenyl]-3-methylbutyl imidazolecarbothioate and 0.0271 g of 2,2'-azobisiso- butyronitrile in 15 ml of toluene. The flask is placed in an oil bath preheated to 120°, and the reaction solution is stirred under reflux for 3 hours. The reaction mixture is then cooled to room temperature, diluted with ethyl acetate and washed with 0.1 M HCI and brine, dried with sodium sulphate and evaporated. The title compound is obtained as a colourless oil from the residue by flash chromatography (SiO2 60F). Rf = 0.33 (EtOAc/heptane 1 :2), Rt = 5.82 (gradient I).
c) O-(2-r2-tert-Butoxycarbonylamine-2-isopropyl-5-oxotetrahvdrofuran-2-yl)ethyl-1-r4- chloro-3-(3-methoxypropoxy)phenyll-3-methylbutyl imidazolecarbothioate
A solution of 0.847 g of tert-butyl [3-{[4-chloro-3-(3-methoxypropoxy)phenyl]hydroxymethyl}- 1-(4-isopropyl-5-oxotetrahydrofuran-2-yl)-4-methylpentyl]carbamate, 0.993 g of 1 ,1'- thiocarbonyldiimidazole and 0.019 g of 4-dimethylaminopyridine in 5 ml of tetrahydrofuran is heated to reflux for 3 hours. A further portion of 1 ,1'-thiocarbonyldiimidazole (0.300 g) is added and then heating to reflux is continued for 3 hours. The reaction mixture is cooled to room temperature, diluted with ethyl acetate, washed with brine, dried with sodium sulphate and evaporated. The title compound is obtained as a yellow foam from the residue by flash chromatography (SiO2 60F). Rf = 0.41 (EtOAc/heptane 1 :1), Rt = 5.53 (gradient I).
d) tert-Butyl r3-(r4-chloro-3-(3-methoxypropoxy)phenyllhvdroxymethyl}-1-(4-isopropyl-5- oxotetrahvdrofuran-2-yl)-4-methylpentyllcarbamate
A solution of 1.311 g of 5-(1-azido-3-{[4-chloro-3-(3-methoxypropoxy)phenyl]hydroxymethyl}- 4-methylpentyl)-3-isopropyldihydrofuran-2-one in 15 ml of tetrahydrofuran is mixed with 0.865 g of triphenylphosphine and 0.064 ml of water. The reaction solution is stirred at room temperature for 16 hours. Water (0.40 ml) is added, and the reaction mixture is then heated to reflux for 8 hours. The reaction mixture is cooled to room temperature, diluted with tert- butyl methyl ether (100 ml) and washed with brine (50 ml), dried with sodium sulphate and evaporated. The residue is dissolved in 20 ml of tetrahydrofuran and, after addition of 0.713 ml of Hϋnig's base and 0.727 g of di-tert-butyl dicarbonate, left to stand at room temperature for 12 hours. The reaction solution is diluted with tert-butyl methyl ether (50 ml) and washed with 0.1 M HCI and brine, dried with sodium sulphate and evaporated. The title compound is obtained as a colourless glass from the residue by flash chromatography (SiO2 60F). Rf = 0.42 (EtOAc/heptane 1 :1), Rt = 5.26 (gradient I).
e) 5-(1-Azido-3-(r4-chloro-3-(3-methoxypropoxy)phenyllhvdroxymethyl}-4-methylpentyl)-3- isopropyldihvdrofuran-2-one 7 g of 4-bromo-1-chloro-2-(3-methoxypropoxy)benzene are reacted in analogy to Method G. The title compound is obtained as a colourless oil. Rf = 0.52 (EtOAc/heptane 1 :1), Rt = 5.27 (gradient I).
f) 4-Bromo-1-chloro-2-(3-methoxypropoxy)benzene
30.22 g of 5-bromo-2-chlorophenol [183802-98-4] are reacted in analogy to Method L. The title compound is obtained as a yellowish oil. Rf = 0.40 (EtOAc/heptane 1 :4), Rt = 5.00 (gradient I).
The following compound is prepared in an analogous manner to the process described in Example 53:
71 5-Amino-7-r4-chloro-3-(3-methoxypropoxy)benzyll-4-hvdroxy-2-isopropyl-8-methyl- nonanoic acid (tetrahydrofuran-2(S)-ylmethyl)amide
Example 73:
5-Amino-4-hvdroxy-2-isopropyl-7-r3-(4-methoxybutyryl)-4-methylbenzyll-8-methylnonanoic acid (tetrahydropyran-4-yl)amide
0.5 mmol of tert-butyl [2-hydroxy-1-{2-[3-(4-methoxybutyryl)-4-methylbenzyl]-3-methylbutyl}- 5-methyl-4-(tetrahydropyran-4-ylcarbamoyl)hexyl]carbamate is reacted in analogy to Method K. The title compound is identified by means of its Rf.
The starting materials are prepared as follows:
a) tert-Butyl r2-hvdroxy-1-(2-r3-(4-methoxybutyryl)-4-methylbenzyll-3-methylbutyl}-5-methyl- 4-(tetrahydropyran-4-ylcarbamoyl)hexyllcarbamate
The title compound is obtained in analogy to Example 30, sequence a-d, from 5-(1-azido-3- {hydroxy[3-(4-methoxybutyryl)-4-methylphenyl]methyl}-4-methylpentyl)-3-isopropyldihydro- furan-2-one and identified by means of its Rf.
b) 5-(1-Azido-3-(hvdroxyr3-(4-methoxybutyryl)-4-methylphenyllmethyl}-4-methylpentyl)-3- isopropyldihvdrofuran-2-one
A solution of 0.62 mmol of 5-[1-azido-3-(hydroxy-{3-[2-(3-methoxypropyl)-[1,3]dioxolan-2-yl]- 4-methylphenyl}methyl)-4-methylpentyl]-3-isopropyldihydrofuran-2-one in 20 ml of acetone is mixed with 20 ml of 2% HCI. The reaction mixture is stirred at room temperature for 45 minutes and poured into saturated sodium bicarbonate solution. It is extracted with dichloromethane (2x) - the combined organic phases are dried with sodium sulphate and evaporated. The title compound is identified by means of its Rf from the residue by flash chromatography (SiO2 60F).
c) 5-ri-Azido-3-(hvdroxy-(3-r2-(3-methoxypropyn-ri ,31dioxolan-2-yll-4- methylphenyl}methyl)-4-methylpentyll-3-isopropyldihvdrofuran-2-one
1 mmol of 2-(5-bromo-2-methylphenyl)-2-(3-methoxypropyl)-[1,3]dioxolane is reacted in analogy to Method G. The title compound is identified by means of its Rf.
d) 2-(5-Bromo-2-methylphenyl)-2-(3-methoxypropyl)-ri ,31dioxolane
A solution of 6.76 mmol of 1-(5-bromo-2-methylphenyl)-4-methoxybutan-1-one in 100 ml of ethylene glycol is mixed with 1 ml of glacial acetic acid. The reaction mixture is stirred at room temperature for 16 hours and poured into saturated sodium bicarbonate solution. It is extracted with dichloromethane (2x) - the combined organic phases are dried with sodium sulphate and evaporated. The title compound is identified by means of its Rf from the residue by flash chromatography (SiO2 60F).
e) 1 -(5-Bromo-2-methylphenyl)-4-methoxybutan-1 -one
1.05 mol of 4-methoxybutanoyl chloride [61882-39-1] are added dropwise to a mixture of 1 mol of 4-bromotoluene [106-38-7] and 1.2 mol of aluminium(lll) chloride at room temperature. The reaction mixture is heated at 50°C for 5 hours. It is then poured into ice. It is extracted with dichloromethane (2x) - the combined organic phases are washed successively with water, 2% NaOH and again with water, dried with sodium sulphate and evaporated. The title compound is identified by means of its Rf from the residue by flash chromatography (SiO2 60F).
The following compound is prepared in an analogous manner to the process described in Example 73:
74 5-Amino-7-r4-ethyl-3-(4-methoxybutyryl)benzylH-hvdroxy-2-isopropyl-8-methyl- nonanoic acid (tetrahvdropyran-4-vl)amide
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001

Claims

What is claimed is:
1. A compound of the formula
Figure imgf000072_0001
in which
R1 is a) saturated heterocyclyl which is optionally substituted one or more times by Ci-8- alkanoyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, Ci-6alkoxy-Ci-6alkoxy, Ci-6alkoxy-Ci-6alkyl, Ci-6alkoxycarbonylamino, Ci-6alkyl, Co-6alkylcarbonylamino, Ci-6alkylcarbonyloxy, Ci-6alkylenedioxy, optionally N-mono or N,N-di-Ci-6-alkylated amino, aryl, optionally N-mono or N,N-di-Ci-6-alkylated carbamoyl, optionally esterified carboxy, cyano, C3-8cycloalkoxy, C3-8cycloalkyl-Co-6alkyl, halogen, halo-Ci-6alkoxy, halo-Ci-6alkyl, heteroaryl, unsaturated, partially saturated or saturated heterocyclyl, hydroxy, nitro, oxide or oxo which is bonded via a C atom; or b) azepanyl-, azetidinyl-, aziridinyl-, dioxanyl-, dioxepanyl-, dioxolanyl-, dithianyl-, dithiolanyl-, furanyl-, oxathianyl-, oxepanyl-, tetrahydropyranyl-, tetrahydrofuranyl-, tetra- hydrothiophenyl-, tetrahydrothiopyranyl-, thiepanyl- or bicyclic saturated heterocyclyl-Ci-4alkyl each of which is optionally substituted one or more times by Ci-8alkanoyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, Ci-6alkoxy-Ci-6alkoxy, Ci-6alkoxy-Ci-6alkyl, Ci-6alkoxycarbonylamino, Ci-6alkyl, C0-6alkylcarbonylamino, Ci-6alkylcarbonyloxy, Ci-6alkylenedioxy, optionally N-mono or N,N-di-Ci-6-alkylated amino, aryl, optionally N-mono or N,N-di-Ci-6-alkylated carbamoyl, optionally esterified carboxy, cyano, C3-8cycloalkoxy, C3-8cycloalkyl-Co-6alkyl, halogen, halo- Ci_6alkoxy, halo-Ci_6alkyl, heteroaryl, unsaturated, partially saturated or saturated heterocyclyl, hydroxy, nitro, oxide or oxo; or c) C2-8alkynyl which is optionally substituted one or more times by Ci-8alkanoyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, Ci-6alkoxy-Ci-6alkoxy, Ci-6alkoxy-Ci-6alkyl, Ci-6alkoxycarbonylamino, Ci-6alkyl, C0-6alkylcarbonylamino, Ci-6alkylcarbonyloxy, Ci-6alkylenedioxy, optionally N-mono or N,N-di-Ci-6-alkylated amino, aryl, optionally N-mono or N,N-di-Ci-6-alkylated carbamoyl, optionally esterified carboxy, cyano, C3-8cycloalkoxy, Cs-scycloalkyl-Co-ealkyl, halogen, halo-Ci-6-alkoxy, halo-Ci-6alkyl, heteroaryl, unsaturated, partially saturated or saturated heterocyclyl, hydroxy, nitro or oxo; or
R2 is, independently of one another, 1-4 radicals selected from:
Ci-8alkanoyl, Ci-8alkanoyl-C2-4alkoxy bearing the alkanoyl group in a position higher than α, Ci-8alkanoylamino-Ci-4alkoxy, N-Ci-4alkanoylamino-Ci-4alkyl, d-salkanoyloxy-d^alkyl, N1-C2-8alkanoylpiperazino-Ci-4alkoxy, N1-C2-8alkanoylpiperazino-Ci-4alkyl, Ci-8alkane- sulphonyl-Ci-4alkoxy, d-8alkanesulphonyl-d-4alkyl, Ci-salkanesulphonylamino-d^alkoxy, Ci-4alkanesulphonylamino-Ci-4alkyl, Ci-8alkanesulphonyl-Ci-4(hydroxy)alkoxy, C2-SaI kenyloxy, C2-8alkenyloxy-Ci-4alkoxy, C2-8alkenyloxy-Ci-4alkyl, Ci-8alkoxy, Ci-6alkoxy-Ci-6alkanoyl, Ci-4alkoxy-C2-4alkenyl, Ci-4alkoxy-C2-4alkenyloxy, Ci-4alkoxy-Ci-4alkoxy, Ci-4alkoxy- Ci-4alkoxy-Ci-4alkyl, d-4alkoxy-d-4alkyl, d-4alkoxycarbonyl-d-4alkoxy, d-4alkoxycarbonyl- Ci-4alkyl, d-βalkoxycarbonylamino-d^alkoxy, d-salkoxycarbonylamino-d^alkyl, d-8alkyl, Ci-4alkylamino, N,N-di-Ci-4alkylamino, Ci-4alkylamino-Ci-4alkoxy, N,N-di-Ci-4alkylamino- Ci-4alkoxy, d-4alkylannino-d-4alkyl, N.N-di-Ci^alkylamino-Ci^alkyl, N-mono- or N,N-di- Ci-4alkylcarbamoyl-Ci-4alkoxy, N-mono- or N.N-di-d^alkylcarbamoyl-d^alkyl, N'-d^alkylpiperazino-d^alkoxy, N'-d^alkylpiperazino-d^alkyl, Ci-4alkylthio-Ci-4alkoxy, Ci-4alkylthio-Ci-4(hydroxy)alkoxy, Ci-4alkylthio-Ci-4alkyl, amino-C2-4alkoxy, amino-Ci-4alkyl, carbamoyl-Ci-4alkoxy, carbamoyl-Ci-8alkyl, carboxy-Ci-4alkoxy, carboxy-d-4alkyl, cyano- Ci-4alkoxy, cyano-Ci-4alkyl, C3-8-cycloalkoxy, C3-8cycloalkoxy-Ci-4alkoxy, C3-8cycloalkoxy- Ci-4alkyl, C3-8cycloalkyl, S,S-dioxothiomorpholino-d-4alkoxy, S.S-dioxothiomorpholino- Ci-4alkyl, halogen, halo-Ci-4alkoxy, halo-Ci-4alkyl, halo-C2-8(hydroxy)alkoxy, hydroxy, hydroxy-C2-8alkoxy, hydroxy-C2-8alkyl, imidazolylthio-d-4alkoxy, imidazolylthio-d-4alkyl, optionally N-oxidized morpholino-Ci-4alkoxy, morpholino-Ci-4alkyl, S-oxothiomorpholino- Ci-4alkoxy, S-oxothiomorpholino-Ci-4alkyl, piperazino-Ci-4alkoxy, piperazino-Ci-4alkyl, piperidino-d-4alkoxy, piperidino-Ci-4alkyl, optionally partially hydrogenated pyridyl- or N-oxidopyridyl-d-4alkoxy, optionally partially hydrogenated pyridyl- or N-oxidopyridyl- Ci-4alkyl, optionally N-oxidized pyridylthio-d-4alkoxy, optionally N-oxidized pyridylthio- Ci-4alkyl, pyrimidinylthio-Ci-4alkoxy, pyrimidinylthio-d-4alkyl, pyrrolidino-Ci-4alkoxy, pyrrolidino-Ci-4alkyl, thiazolinylthio-Ci-4alkoxy, thiazolinylthio-Ci-4alkyl, thiazolyl-Ci-4alkoxy, thiazolylthio-Ci-4alkoxy, thiazolylthio-d-4alkyl, thiomorpholino-Ci-4alkoxy, thiomorpholino- Ci-4alkyl, trifluoro-Ci-βalkanesulphonyl-d^alkoxy, trifluoro-d-8alkanesulphonylamino- Ci-4alkyl, phenyl or naphthyl which is unsubstituted or mono-, di- or trisubstituted by Ci-4alkoxy, d-4alkyl, d-4alkylamino, di-d-4alkylamino, halogen, hydroxy and/or trifluoro- methyl, and phenyl- or naphthyl-d-4alkoxy which is unsubstituted or mono-, di- or trisubstituted by Ci-4alkoxy, Ci-4alkyl, Ci-4alkylamino, di-Ci-4alkylamino, halogen, hydroxy and/or trifluoromethyl, and its salt, prodrug or compound in which one or more atoms are replaced by their stable, non-radioactive isotopes, especially pharmaceutically acceptable salt; excepting compounds in which R1 is optionally substituted N-acetylpiperidin-4-yl or optionally substituted oxopiperidinyl.
2. A compound according to claim 1 of the formula
Figure imgf000074_0001
in which R1 and R2 has the meanings according to claim 1.
3. A compound according to any one of claims 1 or 2, of the formula
Figure imgf000074_0002
in which
R1 has the meaning indicated for the compound of the formula (I) and
R' and R", independently of one another, have the meanings indicated for R2 for the compound of the formula (I).
4. A compound according to any one of claims 1 to 3, in which R2 is, independently of one another, 1-4 radicals selected from: Ci-8alkanoylamino- Ci-4alkoxy, N-Ci-4alkanoylamino-Ci-4alkyl, Ci-8alkoxy, Ci-4alkoxy-Ci-4alkoxy, Ci-4alkoxy- Ci-4alkoxy-Ci-4alkyl, Ci-4alkoxy-Ci-4alkyl, Ci-8alkoxycarbonylamino-Ci-4alkoxy, Ci-8alkoxycarbonylamino-Ci-4alkyl, Ci-8alkyl, halogen, trifluoromethoxy and trifluoromethyl.
5. A compound according to any one of claims 1 to 4, in which
R1 is optionally substituted C2-6alkynyl, optionally substituted saturated bicyclic heterocyclyl- C0-4alkyl, optionally substituted pyrrolidinyl, d-6-alkylated or Cs-scycloalkyl-Co-β-alkylated piperidine, optionally substituted tetrahydrofuranyl, optionally substituted tetrahydrofuranyl- methyl, optionally substituted tetrahydropyranyl or optionally substituted tetrahydropyranyl- methyl.
6. A compound according to any one of claims 2 to 5, in which R' is Ci-4alkoxy-Ci-4alkoxy;
R" is fluorine; and
R1 is optionally substituted tetrahydrofuranylmethyl, optionally substituted tetrahydropyranylmethyl, optionally substituted saturated heterocyclyl which is bonded via a C atom or optionally substituted saturated bicyclic heterocyclyl-Co^alkyl, where the heterocyclyl radical preferably in each case comprises an oxygen atom as heteroatom.
7. The use of a compound of the general formula (I) according to any one of claims 1 to 6 for producing a medicine.
8. The use of a compound of the general formula (I) according to any one of claims 1 to 6 for producing a human medicine for preventing, for delaying the progression or for treating high blood pressure, heart failure, glaucoma, myocardial infarction, renal failure, restenoses or stroke.
9. A method for preventing, for delaying the progression or for treating high blood pressure, heart failure, glaucoma, myocardial infarction, renal failure, restenoses or stroke, where a therapeutically effective amount of a compound of the general formula (I) according to any one of claims 1 to 6 is used.
10. A pharmaceutical product comprising a compound of the general formula (I) according to any one of claims 1 to 6, and usual excipients.
11. A pharmaceutical combination in the form of a product or of a kit composed of individual components consisting a) of a compound of the general formula (I) according to any one of claims 1 to 6, and b) at least one pharmaceutical form whose active ingredient has a cardiovascular effect.
PCT/EP2006/060625 2005-03-11 2006-03-10 Heterocyclic-substituted alkanamides useful as renin inhibitors WO2006095020A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP06725011A EP1856032A1 (en) 2005-03-11 2006-03-10 Heterocyclic-substituted alkanamides useful as renin inhibitors
JP2008500210A JP2008532983A (en) 2005-03-11 2006-03-10 Heterocyclic substituted alkanamides useful as renin inhibitors
BRPI0609158-0A BRPI0609158A2 (en) 2005-03-11 2006-03-10 heterocyclic substituted alkanamides useful as renin inhibitors
US11/885,967 US20080176947A1 (en) 2005-03-11 2006-03-10 Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors
CA002600674A CA2600674A1 (en) 2005-03-11 2006-03-10 Heterocyclic-substituted alkanamides useful as renin inhibitors
IL185769A IL185769A0 (en) 2005-03-11 2007-09-06 Heterocyclic-substituted alkanamides useful as renin inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH0427/05 2005-03-11
CH4272005 2005-03-11
CH1522/05 2005-09-17
CH15222005 2005-09-17

Publications (1)

Publication Number Publication Date
WO2006095020A1 true WO2006095020A1 (en) 2006-09-14

Family

ID=36571037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/060625 WO2006095020A1 (en) 2005-03-11 2006-03-10 Heterocyclic-substituted alkanamides useful as renin inhibitors

Country Status (9)

Country Link
US (1) US20080176947A1 (en)
EP (1) EP1856032A1 (en)
JP (1) JP2008532983A (en)
AR (1) AR053826A1 (en)
BR (1) BRPI0609158A2 (en)
CA (1) CA2600674A1 (en)
IL (1) IL185769A0 (en)
TW (1) TW200700358A (en)
WO (1) WO2006095020A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095876A1 (en) 2004-04-01 2005-10-13 Cucumber Limited Delivery and storage of goods
WO2007031557A2 (en) * 2005-09-17 2007-03-22 Speedel Experimenta Ag Alcanoic acid amides substituted by saturated o-heterocycles
EP1958666A1 (en) * 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
EP2075244A1 (en) 2007-12-24 2009-07-01 DSMIP Assets B.V. New route to building block for making renin inhibitors
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
US7807709B2 (en) 2005-03-23 2010-10-05 Novartis Ag Organic compounds
US8129411B2 (en) 2005-12-30 2012-03-06 Novartis Ag Organic compounds
US8203005B2 (en) 2009-10-29 2012-06-19 Carbo Design Llc Manufacturing process for enantiomerically pure 8-aryloctanoic acids as Aliskiren
US8383650B2 (en) 2007-06-25 2013-02-26 Novartis Ag Organic compounds
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
EP3175849A1 (en) 2013-06-06 2017-06-07 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
US10525041B2 (en) 2016-05-03 2020-01-07 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0678503A1 (en) * 1994-04-18 1995-10-25 Ciba-Geigy Ag Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities
WO2005051895A1 (en) * 2003-11-26 2005-06-09 Novartis Ag Organic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103653A1 (en) * 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
CN101262864A (en) * 2005-09-17 2008-09-10 斯皮德尔实验股份公司 Alcanoic acid amides substituted by saturated O-heterocycles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0678503A1 (en) * 1994-04-18 1995-10-25 Ciba-Geigy Ag Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities
WO2005051895A1 (en) * 2003-11-26 2005-06-09 Novartis Ag Organic compounds

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095876A1 (en) 2004-04-01 2005-10-13 Cucumber Limited Delivery and storage of goods
US7807709B2 (en) 2005-03-23 2010-10-05 Novartis Ag Organic compounds
US8058307B2 (en) 2005-09-17 2011-11-15 Novartis Ag Alcanoic acid amides substituted by saturated O-heterocycles
WO2007031557A2 (en) * 2005-09-17 2007-03-22 Speedel Experimenta Ag Alcanoic acid amides substituted by saturated o-heterocycles
WO2007031557A3 (en) * 2005-09-17 2007-05-24 Speedel Experimenta Ag Alcanoic acid amides substituted by saturated o-heterocycles
US8129411B2 (en) 2005-12-30 2012-03-06 Novartis Ag Organic compounds
EP1958666A1 (en) * 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
US8497286B2 (en) 2007-06-25 2013-07-30 Novartis Ag Organic compounds
US8383650B2 (en) 2007-06-25 2013-02-26 Novartis Ag Organic compounds
EP2075244A1 (en) 2007-12-24 2009-07-01 DSMIP Assets B.V. New route to building block for making renin inhibitors
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
US8203005B2 (en) 2009-10-29 2012-06-19 Carbo Design Llc Manufacturing process for enantiomerically pure 8-aryloctanoic acids as Aliskiren
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
EP3175849A1 (en) 2013-06-06 2017-06-07 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
US10525041B2 (en) 2016-05-03 2020-01-07 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof

Also Published As

Publication number Publication date
IL185769A0 (en) 2008-01-06
AR053826A1 (en) 2007-05-23
EP1856032A1 (en) 2007-11-21
TW200700358A (en) 2007-01-01
BRPI0609158A2 (en) 2010-02-23
CA2600674A1 (en) 2006-09-14
US20080176947A1 (en) 2008-07-24
JP2008532983A (en) 2008-08-21

Similar Documents

Publication Publication Date Title
WO2006095020A1 (en) Heterocyclic-substituted alkanamides useful as renin inhibitors
US8071651B2 (en) 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
EP1717226B1 (en) 2,7-substituted 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octan amide derivatives as renin inhibitors for the treatment of hypertension
RO117791B1 (en) 1-(2-oxo-acetyl)piperidine-2-carboxylic acid derivatives, process for preparing the same, pharmaceutical composition containing them and method of treatment
JP2020180129A (en) TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORγt
BRPI0718460A2 (en) RENINE INHIBITORS
EP3806958B1 (en) 6-aminopyridin-3-yl pyrazoles as modulators of roryt
US20150018340A1 (en) Pipecolate-diketoamides for treatment of psychiatric disorders
CA3103929A1 (en) Phenyl substituted pyrazoles as modulators of roryt
JP3620644B2 (en) Amino acid derivatives and drugs containing them as active ingredients
JPWO2009136625A1 (en) Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
CA3103770A1 (en) Phenyl and pyridinyl substituted imidazoles as modulators of roryt
US20110144197A1 (en) Alcanoic acid amides substituted by saturated o-heterocycles
KR20220118425A (en) nuclear receptor active compounds
NL1024677C2 (en) Therapeutic proline derivatives.
EP1958666A1 (en) Heterocyclic-substituted alkanamides as therapeutic compounds
US20080167381A1 (en) 5-Amino-4-Hydroxy-2-Isopropyl-7-[4-Methoxy-3-(3-Methoxypropoxy)Benzyl]-8-Methylnonamides
KR20050055628A (en) 1-phenylalkyl-piperazines
WO2022234447A1 (en) Nlrp3 inflammasome-inhibiting compounds and the use thereof
EA045146B1 (en) HETEROAROMATIC COMPOUNDS AS VANINE INHIBITORS
JP4214524B2 (en) Amino acid derivatives and drugs containing them as active ingredients
CN116615427A (en) Substituted macrocyclic compounds and related methods of treatment
JPWO2018139438A1 (en) Phenyldifluoromethyl-substituted prolinamide compounds
NZ622539B2 (en) Diphenoxyphenyl derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 185769

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2600674

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11885967

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006725011

Country of ref document: EP

Ref document number: 2008500210

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 7256/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWE Wipo information: entry into national phase

Ref document number: 200680015849.X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006725011

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0609158

Country of ref document: BR

Kind code of ref document: A2